CA2391818A1 - Antagonism of endothelin actions - Google Patents
Antagonism of endothelin actions Download PDFInfo
- Publication number
- CA2391818A1 CA2391818A1 CA002391818A CA2391818A CA2391818A1 CA 2391818 A1 CA2391818 A1 CA 2391818A1 CA 002391818 A CA002391818 A CA 002391818A CA 2391818 A CA2391818 A CA 2391818A CA 2391818 A1 CA2391818 A1 CA 2391818A1
- Authority
- CA
- Canada
- Prior art keywords
- endothelin
- antagonist
- peptidal
- tone
- agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 108050009340 Endothelin Proteins 0.000 title claims abstract description 41
- 102000002045 Endothelin Human genes 0.000 title claims abstract description 41
- ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 title claims abstract description 40
- 230000009471 action Effects 0.000 title claims description 9
- 230000008485 antagonism Effects 0.000 title description 4
- 230000000694 effects Effects 0.000 claims abstract description 37
- 201000001881 impotence Diseases 0.000 claims abstract description 29
- 208000010228 Erectile Dysfunction Diseases 0.000 claims abstract description 24
- 238000011282 treatment Methods 0.000 claims abstract description 19
- 230000001404 mediated effect Effects 0.000 claims abstract description 16
- 239000002308 endothelin receptor antagonist Substances 0.000 claims abstract 12
- 239000005557 antagonist Substances 0.000 claims description 36
- 239000005526 vasoconstrictor agent Substances 0.000 claims description 31
- 108090000623 proteins and genes Proteins 0.000 claims description 28
- 102000004169 proteins and genes Human genes 0.000 claims description 28
- 238000000034 method Methods 0.000 claims description 27
- 108010007647 PD 145065 Proteins 0.000 claims description 18
- 239000002464 receptor antagonist Substances 0.000 claims description 17
- 229940044551 receptor antagonist Drugs 0.000 claims description 17
- 238000004519 manufacturing process Methods 0.000 claims description 16
- 239000003795 chemical substances by application Substances 0.000 claims description 11
- 230000004962 physiological condition Effects 0.000 claims description 11
- 210000005166 vasculature Anatomy 0.000 claims description 11
- 239000003112 inhibitor Substances 0.000 claims description 10
- 230000006444 vascular growth Effects 0.000 claims description 8
- 239000003937 drug carrier Substances 0.000 claims description 6
- 108020000948 Antisense Oligonucleotides Proteins 0.000 claims description 5
- 239000000074 antisense oligonucleotide Substances 0.000 claims description 5
- 238000012230 antisense oligonucleotides Methods 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- 108020004999 messenger RNA Proteins 0.000 claims description 5
- 238000013519 translation Methods 0.000 claims description 5
- 210000001367 artery Anatomy 0.000 claims description 4
- 230000035479 physiological effects, processes and functions Effects 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- ZPHBZEQOLSRPAK-UHFFFAOYSA-N Phosphoramidon Natural products C=1NC2=CC=CC=C2C=1CC(C(O)=O)NC(=O)C(CC(C)C)NP(O)(=O)OC1OC(C)C(O)C(O)C1O ZPHBZEQOLSRPAK-UHFFFAOYSA-N 0.000 claims description 3
- 230000002159 abnormal effect Effects 0.000 claims description 3
- GJPICJJJRGTNOD-UHFFFAOYSA-N bosentan Chemical group COC1=CC=CC=C1OC(C(=NC(=N1)C=2N=CC=CN=2)OCCO)=C1NS(=O)(=O)C1=CC=C(C(C)(C)C)C=C1 GJPICJJJRGTNOD-UHFFFAOYSA-N 0.000 claims description 3
- 229960003065 bosentan Drugs 0.000 claims description 3
- 230000002222 downregulating effect Effects 0.000 claims description 3
- 230000003828 downregulation Effects 0.000 claims description 3
- 108010072906 phosphoramidon Proteins 0.000 claims description 3
- BWSDNRQVTFZQQD-AYVHNPTNSA-N phosphoramidon Chemical group O([P@@](O)(=O)N[C@H](CC(C)C)C(=O)N[C@H](CC=1[C]2C=CC=CC2=NC=1)C(O)=O)[C@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@@H]1O BWSDNRQVTFZQQD-AYVHNPTNSA-N 0.000 claims description 3
- 230000009885 systemic effect Effects 0.000 claims description 3
- 102000017914 EDNRA Human genes 0.000 claims 7
- 101150062404 EDNRA gene Proteins 0.000 claims 7
- 102000017930 EDNRB Human genes 0.000 claims 7
- 101150001833 EDNRB gene Proteins 0.000 claims 7
- 102000048186 Endothelin-converting enzyme 1 Human genes 0.000 claims 6
- 108030001679 Endothelin-converting enzyme 1 Proteins 0.000 claims 6
- 239000002243 precursor Substances 0.000 claims 3
- 206010020772 Hypertension Diseases 0.000 abstract description 16
- 102000008299 Nitric Oxide Synthase Human genes 0.000 abstract description 16
- 108010021487 Nitric Oxide Synthase Proteins 0.000 abstract description 16
- 206010047139 Vasoconstriction Diseases 0.000 abstract description 15
- 230000025033 vasoconstriction Effects 0.000 abstract description 14
- 239000003071 vasodilator agent Substances 0.000 abstract description 14
- 230000007246 mechanism Effects 0.000 abstract description 13
- 229940124549 vasodilator Drugs 0.000 abstract description 13
- 230000001684 chronic effect Effects 0.000 abstract description 11
- 230000024883 vasodilation Effects 0.000 abstract description 9
- 230000001154 acute effect Effects 0.000 abstract description 7
- 230000014509 gene expression Effects 0.000 abstract description 6
- 230000000903 blocking effect Effects 0.000 abstract description 3
- 230000035790 physiological processes and functions Effects 0.000 abstract 1
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 123
- KCWZGJVSDFYRIX-YFKPBYRVSA-N N(gamma)-nitro-L-arginine methyl ester Chemical compound COC(=O)[C@@H](N)CCCN=C(N)N[N+]([O-])=O KCWZGJVSDFYRIX-YFKPBYRVSA-N 0.000 description 28
- 230000002792 vascular Effects 0.000 description 25
- 235000018102 proteins Nutrition 0.000 description 24
- 235000001014 amino acid Nutrition 0.000 description 18
- 229940024606 amino acid Drugs 0.000 description 18
- 150000001413 amino acids Chemical class 0.000 description 18
- 108090000765 processed proteins & peptides Proteins 0.000 description 16
- 230000004044 response Effects 0.000 description 16
- 230000004087 circulation Effects 0.000 description 15
- 238000002474 experimental method Methods 0.000 description 14
- 241000700159 Rattus Species 0.000 description 12
- 210000003899 penis Anatomy 0.000 description 12
- WJAJPNHVVFWKKL-UHFFFAOYSA-N Methoxamine Chemical compound COC1=CC=C(OC)C(C(O)C(C)N)=C1 WJAJPNHVVFWKKL-UHFFFAOYSA-N 0.000 description 11
- 229960005192 methoxamine Drugs 0.000 description 11
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
- 230000018052 penile erection Effects 0.000 description 9
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 8
- 210000002820 sympathetic nervous system Anatomy 0.000 description 8
- 239000002083 C09CA01 - Losartan Substances 0.000 description 7
- XEYBHCRIKKKOSS-UHFFFAOYSA-N disodium;azanylidyneoxidanium;iron(2+);pentacyanide Chemical compound [Na+].[Na+].[Fe+2].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].[O+]#N XEYBHCRIKKKOSS-UHFFFAOYSA-N 0.000 description 7
- KJJZZJSZUJXYEA-UHFFFAOYSA-N losartan Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2[N]N=NN=2)C=C1 KJJZZJSZUJXYEA-UHFFFAOYSA-N 0.000 description 7
- 229960004773 losartan Drugs 0.000 description 7
- 239000011780 sodium chloride Substances 0.000 description 7
- 229940083618 sodium nitroprusside Drugs 0.000 description 7
- 102100040611 Endothelin receptor type B Human genes 0.000 description 6
- 101800004490 Endothelin-1 Proteins 0.000 description 6
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 6
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 6
- VMWNQDUVQKEIOC-CYBMUJFWSA-N apomorphine Chemical compound C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 VMWNQDUVQKEIOC-CYBMUJFWSA-N 0.000 description 6
- 229960004046 apomorphine Drugs 0.000 description 6
- 230000003247 decreasing effect Effects 0.000 description 6
- 230000001419 dependent effect Effects 0.000 description 6
- 230000012010 growth Effects 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 230000010412 perfusion Effects 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 102400000686 Endothelin-1 Human genes 0.000 description 5
- NTSBFTNRWQVBCA-IVGDYKFASA-N His-leu-asp-ile-ile-trp Chemical compound C([C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)[C@@H](C)CC)C1=CN=CN1 NTSBFTNRWQVBCA-IVGDYKFASA-N 0.000 description 5
- 108010003205 Vasoactive Intestinal Peptide Proteins 0.000 description 5
- 102400000015 Vasoactive intestinal peptide Human genes 0.000 description 5
- 210000000702 aorta abdominal Anatomy 0.000 description 5
- KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 description 5
- 230000001186 cumulative effect Effects 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 230000018109 developmental process Effects 0.000 description 5
- 231100000673 dose–response relationship Toxicity 0.000 description 5
- 230000001856 erectile effect Effects 0.000 description 5
- IENZQIKPVFGBNW-UHFFFAOYSA-N prazosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1=CC=CO1 IENZQIKPVFGBNW-UHFFFAOYSA-N 0.000 description 5
- 229960001289 prazosin Drugs 0.000 description 5
- 210000003462 vein Anatomy 0.000 description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 4
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 4
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 4
- 229960004373 acetylcholine Drugs 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 230000017531 blood circulation Effects 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 230000009986 erectile function Effects 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 230000001537 neural effect Effects 0.000 description 4
- 230000001129 nonadrenergic effect Effects 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000004474 valine Substances 0.000 description 4
- 229960003726 vasopressin Drugs 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 3
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 241000283984 Rodentia Species 0.000 description 3
- GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 description 3
- 108010004977 Vasopressins Proteins 0.000 description 3
- 102000002852 Vasopressins Human genes 0.000 description 3
- 230000001800 adrenalinergic effect Effects 0.000 description 3
- 235000003704 aspartic acid Nutrition 0.000 description 3
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 230000036772 blood pressure Effects 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- ZOOGRGPOEVQQDX-KHLHZJAASA-N cyclic guanosine monophosphate Chemical compound C([C@H]1O2)O[P@](O)(=O)O[C@@H]1[C@H](O)[C@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-KHLHZJAASA-N 0.000 description 3
- 210000003038 endothelium Anatomy 0.000 description 3
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 235000013922 glutamic acid Nutrition 0.000 description 3
- 239000004220 glutamic acid Substances 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000002536 noncholinergic effect Effects 0.000 description 3
- 230000036584 pressor response Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000036454 renin-angiotensin system Effects 0.000 description 3
- 230000001228 trophic effect Effects 0.000 description 3
- 230000006442 vascular tone Effects 0.000 description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 2
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 2
- 102000004414 Calcitonin Gene-Related Peptide Human genes 0.000 description 2
- 108090000932 Calcitonin Gene-Related Peptide Proteins 0.000 description 2
- VPGRYOFKCNULNK-ACXQXYJUSA-N Deoxycorticosterone acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)COC(=O)C)[C@@]1(C)CC2 VPGRYOFKCNULNK-ACXQXYJUSA-N 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- 241000700157 Rattus norvegicus Species 0.000 description 2
- 201000001880 Sexual dysfunction Diseases 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000000048 adrenergic agonist Substances 0.000 description 2
- 210000000709 aorta Anatomy 0.000 description 2
- 230000004872 arterial blood pressure Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000001713 cholinergic effect Effects 0.000 description 2
- 210000005226 corpus cavernosum Anatomy 0.000 description 2
- 229960004486 desoxycorticosterone acetate Drugs 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 210000005225 erectile tissue Anatomy 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000001631 hypertensive effect Effects 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 230000008747 mitogenic response Effects 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 239000002858 neurotransmitter agent Substances 0.000 description 2
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 2
- 230000007310 pathophysiology Effects 0.000 description 2
- 239000002831 pharmacologic agent Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 150000003180 prostaglandins Chemical class 0.000 description 2
- 208000002815 pulmonary hypertension Diseases 0.000 description 2
- 230000000284 resting effect Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 231100000872 sexual dysfunction Toxicity 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 210000000278 spinal cord Anatomy 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 230000002889 sympathetic effect Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 239000008399 tap water Substances 0.000 description 2
- 235000020679 tap water Nutrition 0.000 description 2
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 2
- 210000001631 vena cava inferior Anatomy 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- FLVWONZBLRGQPK-VCDBXAJLSA-N (3r,6r,9s,12r,15s)-3-(hydroxymethyl)-6-(1h-indol-3-ylmethyl)-9-(2-methylpropyl)-12-propan-2-yl-1,4,7,10,13-pentazabicyclo[13.3.0]octadecane-2,5,8,11,14-pentone Chemical compound N1C(=O)[C@H](CC(C)C)NC(=O)[C@@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](CO)NC(=O)[C@H]1CC1=CNC2=CC=CC=C12 FLVWONZBLRGQPK-VCDBXAJLSA-N 0.000 description 1
- KHRTUHCOJNQEQG-UHFFFAOYSA-N 2-[12-butan-2-yl-6-(1H-indol-3-ylmethyl)-9-(2-methylpropyl)-2,5,8,11,14-pentaoxo-1,4,7,10,13-pentazabicyclo[13.3.0]octadecan-3-yl]acetic acid Chemical compound N1C(=O)C(CC(C)C)NC(=O)C(C(C)CC)NC(=O)C2CCCN2C(=O)C(CC(O)=O)NC(=O)C1CC1=CNC2=CC=CC=C12 KHRTUHCOJNQEQG-UHFFFAOYSA-N 0.000 description 1
- LKKMLIBUAXYLOY-UHFFFAOYSA-N 3-Amino-1-methyl-5H-pyrido[4,3-b]indole Chemical compound N1C2=CC=CC=C2C2=C1C=C(N)N=C2C LKKMLIBUAXYLOY-UHFFFAOYSA-N 0.000 description 1
- 239000005541 ACE inhibitor Substances 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- ZDILXFDENZVOTL-BPNCWPANSA-N Ala-Val-Tyr Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O ZDILXFDENZVOTL-BPNCWPANSA-N 0.000 description 1
- 102100032381 Alpha-hemoglobin-stabilizing protein Human genes 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- GHODABZPVZMWCE-FXQIFTODSA-N Asp-Glu-Glu Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O GHODABZPVZMWCE-FXQIFTODSA-N 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 229930003347 Atropine Natural products 0.000 description 1
- 108010073982 BQ 610 Proteins 0.000 description 1
- 101800004538 Bradykinin Proteins 0.000 description 1
- 102400000967 Bradykinin Human genes 0.000 description 1
- 206010007572 Cardiac hypertrophy Diseases 0.000 description 1
- 208000006029 Cardiomegaly Diseases 0.000 description 1
- 229920001651 Cyanoacrylate Polymers 0.000 description 1
- AGPKZVBTJJNPAG-CRCLSJGQSA-N D-allo-isoleucine Chemical compound CC[C@H](C)[C@@H](N)C(O)=O AGPKZVBTJJNPAG-CRCLSJGQSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 206010014824 Endotoxic shock Diseases 0.000 description 1
- 241001635598 Enicostema Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010078321 Guanylate Cyclase Proteins 0.000 description 1
- 102000014469 Guanylate cyclase Human genes 0.000 description 1
- QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 description 1
- 102000015779 HDL Lipoproteins Human genes 0.000 description 1
- 108010010234 HDL Lipoproteins Proteins 0.000 description 1
- 101000797984 Homo sapiens Alpha-hemoglobin-stabilizing protein Proteins 0.000 description 1
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 1
- 108010065069 JKC 301 Proteins 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- 229930064664 L-arginine Natural products 0.000 description 1
- 235000014852 L-arginine Nutrition 0.000 description 1
- 241000283986 Lepus Species 0.000 description 1
- WXZOHBVPVKABQN-DCAQKATOSA-N Leu-Met-Asp Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(=O)O)C(=O)O)N WXZOHBVPVKABQN-DCAQKATOSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- GJJQCBVRWDGLMQ-GUBZILKMSA-N Lys-Glu-Ala Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(O)=O GJJQCBVRWDGLMQ-GUBZILKMSA-N 0.000 description 1
- MWCLLHOVUTZFKS-UHFFFAOYSA-N Methyl cyanoacrylate Chemical compound COC(=O)C(=C)C#N MWCLLHOVUTZFKS-UHFFFAOYSA-N 0.000 description 1
- 206010027626 Milia Diseases 0.000 description 1
- 108020001621 Natriuretic Peptide Proteins 0.000 description 1
- 102000004571 Natriuretic peptide Human genes 0.000 description 1
- 101100022915 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) cys-11 gene Proteins 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- YRKFKTQRVBJYLT-CQDKDKBSSA-N Phe-Ala-His Chemical compound C([C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1NC=NC=1)C(O)=O)C1=CC=CC=C1 YRKFKTQRVBJYLT-CQDKDKBSSA-N 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- WTTRJMAZPDHPGS-KKXDTOCCSA-N Tyr-Phe-Ala Chemical compound C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(O)=O WTTRJMAZPDHPGS-KKXDTOCCSA-N 0.000 description 1
- 206010072810 Vascular wall hypertrophy Diseases 0.000 description 1
- 206010047141 Vasodilatation Diseases 0.000 description 1
- 102000004136 Vasopressin Receptors Human genes 0.000 description 1
- 108090000643 Vasopressin Receptors Proteins 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000000674 adrenergic antagonist Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 108010070944 alanylhistidine Proteins 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 229940127088 antihypertensive drug Drugs 0.000 description 1
- 210000002376 aorta thoracic Anatomy 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 108010092854 aspartyllysine Proteins 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 1
- 229960000396 atropine Drugs 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000002567 autonomic effect Effects 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 150000003943 catecholamines Chemical class 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000001447 compensatory effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- FMGSKLZLMKYGDP-USOAJAOKSA-N dehydroepiandrosterone Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC=C21 FMGSKLZLMKYGDP-USOAJAOKSA-N 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 210000003989 endothelium vascular Anatomy 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 108010049041 glutamylalanine Proteins 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 230000001969 hypertrophic effect Effects 0.000 description 1
- 210000003090 iliac artery Anatomy 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 230000030214 innervation Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 239000007926 intracavernous injection Substances 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 150000002617 leukotrienes Chemical class 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000692 natriuretic peptide Substances 0.000 description 1
- 210000004126 nerve fiber Anatomy 0.000 description 1
- 230000003767 neural control Effects 0.000 description 1
- 230000036403 neuro physiology Effects 0.000 description 1
- 230000002182 neurohumoral effect Effects 0.000 description 1
- 230000004751 neurological system process Effects 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000001734 parasympathetic effect Effects 0.000 description 1
- 210000005037 parasympathetic nerve Anatomy 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000004796 pathophysiological change Effects 0.000 description 1
- 230000001991 pathophysiological effect Effects 0.000 description 1
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
- 210000000578 peripheral nerve Anatomy 0.000 description 1
- 230000002572 peristaltic effect Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 229960001802 phenylephrine Drugs 0.000 description 1
- SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 description 1
- 230000001242 postsynaptic effect Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000003518 presynaptic effect Effects 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 201000011264 priapism Diseases 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 230000004648 relaxation of smooth muscle Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000009291 secondary effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000009329 sexual behaviour Effects 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-N sodium;5-ethyl-5-pentan-2-yl-1,3-diazinane-2,4,6-trione Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)NC1=O QGMRQYFBGABWDR-UHFFFAOYSA-N 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000003699 striated muscle Anatomy 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000008700 sympathetic activation Effects 0.000 description 1
- BFKJFAAPBSQJPD-UHFFFAOYSA-N tetrafluoroethene Chemical compound FC(F)=C(F)F BFKJFAAPBSQJPD-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000003106 tissue adhesive Substances 0.000 description 1
- 210000001585 trabecular meshwork Anatomy 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 238000009424 underpinning Methods 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 230000004218 vascular function Effects 0.000 description 1
- 230000004865 vascular response Effects 0.000 description 1
- 208000000331 vasculogenic impotence Diseases 0.000 description 1
- 230000002227 vasoactive effect Effects 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 1
- 229960001600 xylazine Drugs 0.000 description 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The mechanism of hypertension following acute NO synthase blockade is via endothelin-mediated vasoconstriction. Thus, NO appears to inhibit endothelin activity by blocking its expression and not as a chronic direct acting vasodilator.
Administration of an endothelin antagonist to a patient in a 'normal' physiological state may result in specific regional vasodilation. This treatment finds utility in the treatment of erectile dysfunction.
Administration of an endothelin antagonist to a patient in a 'normal' physiological state may result in specific regional vasodilation. This treatment finds utility in the treatment of erectile dysfunction.
Description
ANTAGONISM OF ENDOTHELIN ACTIONS
FIELD OF THE INVENTION
')'his application is a continuation-in-part of U.S.S.N. 08/615,659 filed March 13, 1996, the contents of which are hereby incorporated herein by reference.
This invention relates to methods fo.r down-regulating local endothelia-mediated vasoconstrictor and/or vascular growth activity in "apparently" normal physiological canditions in order to re-establish normal control in specific regions of the circulation which demonstrate pathophysiology. More particularly this invention relates to the administration of agents which antagonize the expression or activity of endothelia for the treatment of abnormalities of specific regions of the vasculature such as in erectile dysfunction in male patients.
BACKGROUND OF INVENTION
Endothelins were first described in 1988 and have been shown to be powerful vasoconstrictors, predominantly found in the vascular endothelium. and, since that time, numerous endothelia antagonists and pharmaceutically acceptable salts thereof have been identified and can be obtained commercially (e.g., Sigma, American Peptides).
Attention is also directed to U.S. Patents No. 5,284,828 issued 8 February 1994 to Hemmi et al., No. 5,378,715 issued 3 January 1995 to Stein et al. and No. 5,382,569 issued 17 January 1995 to Cody et u1., which describe in detail the chemical structures of various endothelia antagonists, and to U.S. Patent No. 5,338,726 issued 16 August 1994 to Shinosaki et al., which describes the chemical structure of endothelia converting enzyme inhibitors, the disclosures of which are incorporated herein by reference. To date, however, antagonists of endothelia have not been approved for therapeutic use, although a number of investigators have postulated that endothelia antagonists could be used for conditions ranging from renal failure, endotoxic shock, asthma, angina, or diabetes to pulmonary hypertension and possibly other indications.
Under normal physiological conditions, endothelia can be found in almost all parts of the circulation at very low levels. In general, in the normal rodent circulation endothelia (ET) is not found in elevated quantities and appears to have minimal effect in the normal regulation of vascular tone, i.e., there is no appreciable decrease in blood pressure when an endothelia antagonist is administered by injection in normal circulation.
Further, at present there does not appear to be any evidence suggesting that E'r plays a physiological role even in a small portion of the circulation under normal conditions in experimental models. However, it is likely that the circulation may appear normal when in fact a specific region of the circulation reveals pathophysiological changes, such as occurs with erectile dysfunction. Penile erection demands specific local vasodilation and/or inhibition of local vasoconstrictor mechanisms. It is not surprising that findings of elevated levels of endothelia in the blood are not widespread, as the regulation of ET action indicates a release preferentially towards the smooth muscle side, away from the circulation. In addition, it is highly improbable that there would be increased ET found in the circulation resulting from increased activity in a small portion of the circulation. ET is known to have a very short half-life.
It is widely known that administration of nitric oxide (NO) can provoke powerful vasodilator responses. The chronic role of nitric oxide synthase (NOS) as a vasodilator has only been inferred by indirect means, i.e., by removal of the NOS activity.
Endogenously, there is much more redundancy in control of vasodilatation. For example, vasodilation can be induced by acetylcholine, bradykinin, adenosine triphosphate (ATP), histamine, vasoactive intestinal polypeptide (VIP), and leukotrienes, amongst others. The actions of these endogenous modulators have been shown to be dependent on the presence of the endothelium, an effect likely mediated by endothelial derived relaxing factor /NO
(EDRF/NO) (1,2,3). Other vasodilator mechanisms exist which are not endothelium dependent, such as ~i2-adrenergic, anal natriuretic peptide (ANP) and certain prostaglandins. The actions of NO appear to be mostly cGMP-mediated via guanylate cyclase activation, although other mechanisms have been suggested. Garg and Hassid ( 1, 2) and others (4,5) demonstrated a difference in the effects of NO-generating vasodilator agents in inhibiting vascular smooth muscle cell growth in culture; however, it is clear that NO can act not only as a vasodilator but also to inhibit vascular growth responses in a number of conditions (6).
In the last several years a large number of studies has demonstrated that decreased NO production using inhibitors of NO synthase (e.g., N"-vitro-L-arginine-methyl ester or L-NAME) produces dose-dependent hypertension (i.e., L-arginine reversible, and which correlates with decreased cyclic guanosine monophosphate (cGMP)) (7,8,9). Data from Schiffrin's (4,10) and Morton's ( 11 ) groups demonstrate that prolonged high dose L-NAME hypertension is associated with hypertrophic changes in the mesenteric vasculature ( 1 media thickness and t media/lumen ratio). Interestingly, Schiffrin's group found that the degree of change in vascular structure was less marked than in other models (2I<1C) with equivalent hypertension and of a similar duration. rl'aken together with the findings of NO development of cardiac hypertrophy and slower vascular changes, current evidence indicates that L-NAME hypertension is quite different from other models.
Further, although these findings could suggest a rote for NO as a modulator of vascular structure, our recent findings suggest that NO may play a more important inhibitory role in suppressing the activity of the endothelia vasoconstrictor system. The concept of NO
suppression of ET expression is further supported by evidence both from Luscher's group in vitro and from the Clozel group (12) in vivo showing that there is increased release of ET
from endothelial cells afl.~~',_1y0~ _blockage. These data suggest that exogenous administration of NO synthase antagonists produces a condition wherein the lack of NO
appears to be a modulator of ET expression and release. Recent findings, in particular from Schiffrin's group ( 13,14), in deoxycorticosterone acetate (DOCA)-salt hypertension point to a trophic role for endogenous endothelia in the development of vascular structural changes. They found that there is increased ET-1 gene expression and immunoreactivity in blood vessels, but not in the plasma, of DOCA-salt hypertensive rats, whereas renin angiotensin system (RAS) activity was decreased. There was a substantial development of vascular hypertrophy in the DOCA-salt model which was markedly attenuated by treatment with an ETp/ETB receptor antagonist. The concept that ET-1 is a vascular trophic factor is further supported by findings in studies with cultured vascular smooth muscle cells showing that addition of endothelia produces a mitogenic response ( 15), as well as findings in other in vivo studies indicating a role in structural changes associated with pulmonary hypertension ( 1 b). ET-1 is approximately 100 times more potent as a vasoconstrictor than Ang II or catecholamines. Interestingly, in the culture studies, although the maximal growth response to ET-1 was less than half of that for Ang II, the combination of ET-1 plus Ang II provoked a greater mitogenic response than either peptide alone. We are not aware of any studies that have assessed the in vivo cardiovascular growth responses to direct endothelia infusion.
An important aspect of the invention derives from the development of a concept which reveals an interrelationship between NO activity and endothelia vasoconstrictor activity, in vivo: specifically, that NO acts primarily as a chronic inhibitor of endothelin-mediated vasoconstriction, and less as a chronic vasodilator. Accordingly, it is proposed that endothelia plays a role in disease conditions associated with impaired NO
synthesis, particularly if the pathophysiology is restricted to a specific portion of the circulation; i.e., if the entire circulation were altered, numerous compensatory changes in neurohumoral systems would also occur.
Our hypothesis is that if NO synthesis is inhibited, a significant increase in mean arterial pressure (MAP) is the result of increased endothelia release and this MAP increase can be eliminated by administration of an endothelia antagonist. It is apparent, therefore, that administration of an endothelia antagonist in physiological conditions where NO
production is inhibited will result in vasodilation ONLY in the regions which have upregulated ET activity consequent, in part, to a down regulation of local NO
production.
Physiological conditions where NO production is inhibited in a local circulation, such as male erectile dysfunction, indicate that suppression of endothelia activity would offer an effective treatment.
Based on the understanding that a significant portion of the underlying problem in clinical erectile function relates to "vascular" mechanisms, much of the current state-of-the-art research involves determining the contribution that the different vascular effector control systems make in normal and pathophysiological states. There is substantial understanding of the hemodynamic events that lead to an erection, and yet the quantitative roles of each of the neuroeffector, humoral and local systems in these events remain poorly described. Since 1990, nitric oxide (NO) has been considered the primary non-adrenergic non-cholinergic neurotransmitter in the penis and has been presumed to be the primary mediator of corporal relaxation during erection.
The issue of "impotence" was discussed at the National Institutes of Health (NIH) in Washington in December 1992 (defined as "a pattern of persistent or recurrent inability to develop or maintain an erection of sufficient rigidity for successful coitus") and has clearly been identified as having a wide range of causative or associated factors. The Massachusetts Male Aging Study (MASS) has provided us with an updated view of the epidemiology of erectile dysfunction although there seem to be some unchangeable truths -it is accepted that the prevalence of impotence increases with age (IGnsey, 1948) (17).
Complete erectile dysfunction (ED) increases from 5 to 15% between 40 and 70 years of age, Feldman, 1994 ( 18). ED has been shown to be "directly correlated with heart disease, hypertension, diabetes, associated medications, indices of anger and depression, and inversely with serum dehydroepiandosterone, high density lipoprotein, cholesterol and an index of dominant personality."
It is now estimated that in North America there are more than 30,000,000 men with ED, a significant increase from the figure of 10,000,000 used just 10 years ago (Shabsigh et al., 1988 (19); Whitehead, 1988 (20); Furlow, 1985 (21)). From these figures it is also reasonable to estimate that as many as three million Canadian men may have a degree of ED. The direct cost of treating impotence is impressive. Reliable figures for 1985 show that the cost of treating impotence exceeded 146 million dollars in the United States in that year alone (National Center for Health Statistics) and this number is just the estimated market size for one type of injectable therapy. The secondary effects and indirect costs associated with erectile dysfunction would suggest that impotence and sexual dysfunction are medical icebergs. The consequences of sexual dysfunction may be seen in strains on the host relationship potentially leading to marital breakdown, violence, work related sequelae, deviant sexual behavior, and impacts on children, when present, that can carry the damage into a new generation of unwanted behaviors. If ED underlies even a small but significant percentage of marital and family breakdown, then it adds vastly to the social and economic burden in society. The pragmatic issue is that large numbers of men are now being treated for ED and most of the treatments are fairly blunt instruments (intracavernosal injection (ICI) of mixed vasoactive compounds, penile prosthesis insertion) with significant cost and complications (ICI: pain, priapism, dislike of the technique; prostheses: reoperation, infection, distortion of body image).
As a medical and scientific problem, ED gained greatly in stature when Rajfer et al.
(1992) (22) published their information linlting nitric oxide (NO) with normal erectile function. It was an interesting coincidence that NO became "Molecule of the Year" that same year as a result of the accumulated and established work in other vascular systems.
This heralded a new maturity in the study of ED - suddenly the principles of normal vascular biology (NVB) became accepted as the underpinnings of erectile physiology.
The Physiological Basis of Penile Erection The stimulus to erection is central and neural in origin. A fully functional penile erection requires coordinated input from various levels of the central nervous system and at least three sets of peripheral nerves (thoracolumbar sympathetic, saccral parasympathetic, and pelvic somatic). Adrenergic, non-adrenergic and non-adrenergic non-cholinergic neurotransmitter systems of importance have been identified in the cavernous tissue (Saenz de rhejada, 1988) (23). An excellent account of the neural processes (without specific roles) involved in the production of a penile erection can be found in the review by deGroat and Steers (1988) (24).
A penile erection is dependent upon the integration of anatomic, vascular (hydraulic; arterial and venous), endocrine, neurologic and hormonal mechanisms. The erectile components of the penis are the corpora cavernosa and the corpus spongiosum.
The latter contributes little to the rigidity of the penis when erect. The corpora cavernosa are paired cylinders that are firmly and separately anchored to the inferior pubic rami at their proximal roots, where they are covered by striated muscle (ischiocavernosus), become joined in the proximal pendulous shaft and fenestrated (i.e., functionally connected) distally. There is usually one supplying end-artery per cavernosal body, from the internal iliac artery, that branches to become the deep penile artery which has at least two types of branches within the cavernosa: The venous drainage of the corpora is through the intermediate system for the distal cavernosa and plans and through the deep system for the remaining cavernosae. 'The critical venous channels are the subtunical veins, which empty through emissary veins that pass through the tunica and drain into the deep dorsal vein. It is the emissary veins that are compressed during erection and permit the "locked" state of veno-occlusion.
It is well established that, for erection, neurally mediated (autonomic) vasodilation of the penile arterial blood vessel and the trabecular meshwork takes place (Lue et al. , 1987) (25) permitting extra blood flow into the cavernous bodies of the penis.
The expanding intracorporal volume traps the effluent veins that lie between the erectile tissue and the surrounding, relatively inelastic, fibrous tunica albuginea. The outflow capacity is thereby decreased and entrapment of blood ensues, resulting in the transformation of the flaccid penis into its erect state (Juenemann et al., 1986 (26); Lue et al., 1987 (25); Lue et rtl., 1983 (27); Weiss, 1980 (28)). Inflow arterial tone is of absolute importance in this process, although adequate driving blood pressure (BP) is a necessary factor.
The converse, detumescence, is mediated by the sympathetic nervous system (Saenz de Tejada, 1988 (23); Juenemann et al., 1989 (29)) and is dependent on the metabolic viability of cells within the erectile tissue. A maximal direct pharmacological vasodilator stimulus may b not produce an erection in a penis driven by the high sympathetic nervous system activity state induced by fear. Thus, it is not surprising that alterations in blood flow and vascular dynamics, whether produced by decreased cardiac output, reFlex sympathetic hyperactivity, atherosclerosis, untreated hypertension, antihypertensive medication or, as herein proposed, increased local endothelia-mediated vasoconstriction, can produce profound effects on the ability of the flaccid penis to be transformed into the erect state.
Penile control systems The known control systems for erection are conventionally described under the headings: adrenergic, cholinergic and non-adrenergic non-cholinergic (NANC).
Adrenergic IO nerve fibers and high concentrations of norepinephrine can be found in the corpora (Melman and Henry, 1979 (30); Benson et al., 1980 (31 )) and the contractile properties of phenylephrine are established unequivocally (Hedlund et al., 1984 (32); Christ et al., 1990 (33)) with post-synaptic al effects acting directly and pre-synaptic a2 modulation.
Previously, parasympathetic nerves were thought to be the nerves responsible for erection (Wagner et al., 1980 (34)), although the in vitro effects from acetylcholine (ACh) were varied in early experiments (Adaikan et al., 1983 (35); Hedlund et al., 1985 (32)). Further, simple intracorporal injection of acetylcholine does not cause erection and atropine does not block it (Wagner et al., 1980) (34). Thus, cholinergic nerves are described as modulators of neural function. Accordingly, NANC innervation, as the pre-eminent player in erectogenesis, has received intense scrutiny and the current thinking is that nitric oxide has replaced VIP as the prime vasodilator of this system in the penis. rI his view was first published by Ignarro et al. (36) and has been re-stated many times since. Not surprisingly, a variety of other NANC systems have also been shown to play a role in erectile function, including vasoactive intestinal polypeptide (VIP) (Gu et al., 1983 (37) &.4 (38); Willis et al., 1983 (39)), calcitonin gene related peptide (CGRP) (Stief, 1990) (40) and the prostaglandins (Hedlund and Andersson, 19$5) (41). The terms that have been used to describe the neuroeffector systems and the roles they play provide an historic basis for descriptions of penile systems but have not removed the confusion that is found in the more than 100 relevant papers that have been published since 1990 on neural regulation.
It is without doubt that penile erections occur when arterial dilation and smooth muscle relaxation take place. The penis is an ideal vascular bed to consider in terms of the physiological opposition of neural effector systems involved in both relaxation and contraction i.e the penis is one of only a small handful of special circulations with dual vasoconstrictor and vasodilator neural control systems. ?'o fully characterize the penile control systems, a greater understanding of the countervailing systems both in a clinical and an experimental setting is required in order to elucidate the critical balance and interdependence that are essential for normal function.
As described, in order for penile tumescence to occur, the pudendal vascular bed must vasodilate to shunt blood flow to the cavernosal tissue. Normal vascular beds have a balance of vasodilators and vasoconstrictors regulating the level of vascular tone.
Upsetting of this balance can lead to an enhanced chronic vasoconstrictor response.
Chronic erectile dysfunction creates a situation where the penile vascular bed has seen chronic low oxygen partial pressures pOz. Low p02 has been shown to decrease the activity of NO synthase and hence NO production. Further, it has also been shown, in rats, that the activity of the NO synthase enzyme decays with age. Both of these concepts in combination with our novel findings indicate a key role for enhanced endothelin-mediated vasoconstriction. Once enhanced endothelin occurs, there are three levels of mechanisms that will sustain the erectile dysfunction: (l) enhanced vasoconstriction in the penile vascular bed occurs, making it more 'difficult' for the vasodilators to shunt blood to the penis to facilitate cavernosal filling (this is also a positive feedback loop with respect to NO synthase since less blood flow will maintain low p01 values); (ii) endothelin has been shown in vitro and in vivo to promote cardiovascular growth processes. This could lead to a structural change where blood vessels grow and encroach on the lumen, leading to increased resistance due to a structural mechanism (as opposed to chronic vasoconstriction); and (iii) enhanced endothelin may act as a 'primer' for other vasoconstrictor systems (renin-angiotensin system and sympathetic nervous system) which additionally act as trophic factors (i.e., the endothelin may prime the vascular bed such that Ang II, for example, will promote growth at doses that by themselves would not normally induce growth processes).
In summary, an upregulation of endothelin actions occurs when the production of NO is inhibited. This chronic enhanced endothelin, we propose, will be involved in mediating the changes leading to erectile dysfunction. Acutely, there will be enhanced vasoconstriction via the endothelium (endothelin) and, in the longer term, endothelin-mediated growth responses in the vascular tissue. The penile vascular tissue would, therefore, go through a structural change such that it. would become more and more difficult to cause vasodilation with the progression of encroachment into the lumen of the vessels leading to the penis, as well as in the corpus cavernosal tissue itself.
There are several approaches that lead to the down regulation of the activity of endothelia, namely (a) peptide antagonists such as PD 145065 (Parke Davis), (b) non-peptide antagonists such as bosentan (Hoffman-LaRoche) (42), (c) inhibitors of endothelia converting enzyme, such as for example phosphoramidon (i.e., blocking production of endothelia) and (d) antisense oligonucleotides which specifically block the translation of the endothelia protein at the genetic level, i.e., disrupt the normal cycle of evems with preproendothelin mRNA.
BRIEF STATEMENT OF INVENTION
Thus, it is an object of the present invention to provide a method for treating physiological conditions in which NO production is at least partially inhibited, such as, but not limited to, erectile dysfunction (ED).
Another object of this invention is to provide compositions of matter for the treatment of physiological conditions in which NO production is at least partially inhibited.
By one aspect of this invention, there is provided a method for treating physiological conditions in which NO production is at least partially inhibited, comprising administering to a patient in need thereof an effective amount of an agent which will antagonize the actions of endothelia (antisense to ET-mRNA, or ET antagonists, ECE
antagonists).
By another aspect of this invention, there is provided a composition for use in the treatment of physiological conditions in which NO production is at least partially inhibited, comprising an effective amount of an endothelia antagonist or pharmaceutically acceptable salt thereof in admixture with a pharmaceutically acceptable carrier therefor.
In a preferred aspect, said physiological condition is erect.ile disfunction.
BRIEF DESCRIPTION OF DRAWINGS
Figure 1 is a block diagram illustrating MAP response with vasoconstrictor blockade (n = 8, 8);
Figure 2a is a graph illustrating MAP response with L-NAME pretreated with losarfan or PD 145065, (n = 6, 6);
Figure 2b is a graph illustrating MA1' response after treatment with L-NAME
followed by 1'D145065;
Figure 3 is a graph illustrating the cumulative dose response to methoxamine, n =
6; and Figure 4 is a graph illustrating tine cumulative dose response to endothelin, n = 4.
DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS
It is known that, in vivo, several systems contribute to vascular tone and mean arterial pressure (MAP). These systems include the sympathetic nervous system (SNS), renin-angiotension system and the vasopressin system. As described in more detail hereinafter, the contribution of each of these different systems to an experimentally induced pressure increase of 30-40% in rats as a result of NO synthase (NOS) inhibition with N"-vitro-L-arginine-methyl ester (L-NAME, Sigma Chemicals) has been assessed. If NO production is inhibited, a significant increase in MAP must be the result of endothelin release, since this MAP increase is eliminated when an endothelia antagonist is added.
Thus, it has been established that NO acts to chronically (locally) down-regulate the release of endothelia, not as a chronic direct acting vasodilator. 'The contribution of endothelia induced vasoconstriction to L-NAME hypertension was assessed by administering an ET,,~ETB receptor antagonist such as PD 145065 (Parke Davis Pharmaceuticals) in a pharmaceutically acceptable carrier therefor, both before and after NO synthase inhibitor "inhibition". Suitable carriers include water and isotonic dimethyl sulfoxide (DMSO). PD145065 is a peptide and hence not readily bioavailable by oral administration. Non-peptide receptor antagonists would be better choices for oral administration. PD 145065 may be effectively administered by intravenous administration.
It will be appreciated that, in the experiments described below, an ETA/ETB
receptor antagonist was used in order to control for any transient vasodilation which might occur via an ET8 receptor, and which would skew the estimation of involvement in hypertension following NO synthase blockade. It is believed, however, that ETA or ETB
receptor antagonists alone would also, at least in part, suppress the endothelia induced vasoconstriction.
ETA and ETB antagonists are available commercially from various sources such as American Peptide Company Inc. and include:
.a ETA
NAME FORMULA CAT NO.
Endothelia Antagonist c(DTrp-DAsp-Pro-DVaI-Leu) (SEQ ID NO: 1 ) 88-2-10 Endothelia Receptor c(DGIu-Ala-Allo-Dlle-Leu-DTrp) (SEQ ID NO: 2) 88-2-20 Antagonist (BE18257B) Endothelia Antagonist (JKC-301 ) c(Dlle-Leu-DTrp-DAsp-Pro) (SEQ ID NO: 3) 88-2-Endothelia Antagonist (JKC-302) c(DVaI-Leu-DTrp-DSer-Pro) (SEQ ID NO: 4) 88-2-Endothelia Antagonist (BQ-610) (N,N-hexamethylene)carbamoyl-Leu-DTrp(CHO)-DTrp (SEQ ID NO: 5) 88-2-32 Endothelia Receptor Antagonist c(DGIu-Ala-DVaI-Leu-DTrp) (SEQ ID NO: 6) 88-2-(W-7338A) EIB
NAME FORMULA CAT NO.
[Cys11,Cys 15] Endothelia-1 c(DGIu-Ala-DVaI-Leu-DTrp) (SEQ ID NO: 7) 88-2-41 (8-21 ), (1 RL-1038) [A1a11,15] Endothelia-1 (6-21), Ac-Leu-Met-Asp-Lys-Glu-Ala-Tyr-Phe-N-Acetyl Ala-His-Leu-Asp-Ile-Ile-Trp (SEQ ID NO: 8) 88-2-42 N-Suc-[GIu9,Ala11,15]Endothelia- Suc-Asp-Glu-Glu-Ala-Val-Tyr-Phe- 88-2-50 1, (8-21 ), (LRL-1620) Ala-His-Leu-Asp-Ile-Ile-Trp (SEQ ID NO: 9) Methods Animals Male Sprague-Dawley rats (325-400g) obtained from Charles River Laboratories (Montreal, Quebec, Canada) were housed individually under conditions of a 12 h light/12 h dark cycle, with room temperature at 22-24°C, and were provided with Purina Rodent Chow and tap water ad libitum for at least 2 days before any experiments were started.
Measurement of MAP and Short Actin, DrueAdministration The surgical method was based on the technique of Thompson et al.
(Hypertension 20: 809-815 ( 1992)). In brief, rats were anesthetized with ketamine/xylazine (70/5 mg/kg i.p.), and the descending aorta distal to the kidneys was catheterized with small bore TEFLON~ tubing (0.012-in. i.d., o.d. 30 gauge, Cole-farmer, Laval, Quebec, Canada) inserted into vinyl tubing (0.02-in. i.d., 0.060-in. o.d., 23 gauge). The inferior vena cava was also catheterized distal to the kidneys with small bore rl'EFLONO tubing (0.012-in.
i.d., o.d. 30 gauge, Cole Parmer). The catheters were filled with heparinized saline ( 10 IU/mL) and held in place by a small amount of cyanoacrylate tissue glue at the puncture site. The catheters were tunneled subcutaneously and exteriorized at the back of the neck and sutured in place. Two days after surgery, MAf could be recorded (Narco Physiograph, E&I Instruments, Houston, TX or MacLab Data Acquisition System, ADInstruments, Milford, MA, U.S.A.). After connection, an equilibration period of approximately 30 min was allowed for the determination of the steady state level of MAP before any recording began. Baseline MAP was determined from mean readings over 5 min, taken from each rat at I5 min intervals for at least 1 h prior to the start of any experiment.
After obtaining a baseline MAP, the cumulative/sequential vasoconstrictor blockade was started.
MAP
values are expressed as an average MAP over 2-3 min following the establishment of a new steady state (i.e., MAf is no longer changing).
Experiment I : Cumulative vasoconstrictor blockade following acute NO
inhibition NOS was inhibited by a single i.p. injection of N''-vitro-L-arginine-methyl ester (L-NAME, Sigma, 100 mg/kg; 100 mg/mL 0.9% sterile saline solution, Baxter Corp., Toronto, Ontario, Canada). The ai-adrenoceptor antagonist prazosin~ (Sigma Chemical Company, St. Louis, MO, U.S.A.) at a dose of 1 mg/kg (in 0.9% saline and 5% ethanol [vol/vol], total volume 1 ml~kg) was used to block the majority of the SNS induced peripheral vasoconstriction. The non-peptide AT, receptor antagonist losartan~ (Dupont-Merck, 30 mg/kg i.p.) was used to block the effects of Ar<g II. The ';/V2 receptor antagonist [(3-mercapto-(3, [3-cyclopenta-methylenepropionyl, O-Et-Tyre-Val4-ArgB]-vasopressin (AVP) (20 ~eg/lcg/min i.v., Sigma) was utilized to block the effects of vasopressin.
The effects of the endothelia vasoconstrictor system, via ETA and ETB receptors, were blocked with a commercially available endothelia antagonist fD 145065 (100 mg/k~min i.v., bolus, donated by Parke-Davis Pharmaceuticals). Each rat in the study received all of the aforementioned vasoconstrictor antagonists (i.e., a cumulativeJsequential blockade). The addition of sodium nitroprusside (SNP) (200 ~cg/kg i.v. 0.3 c.c. bolus, Sigma) was used to transiently lower MAP to the level of minimum vascular resistance across all treatment groups (i.e., where the level of MAP becomes predominantly dependent on cardiac output at minimum vascular resistance; MAl',",;" = CO x'rl'1~";"). Not surprisingly, this value was found to be similar across all treatment groups and enabled the calculation of the total range of MAP pressure lowering (MAI~a"gp=MAl'-MAP",;"). As well, the addition of SN1' reveals the activity of 'other' vasoconstrictor systems that might not have been accounted for but may be important in contributing to the level of MAl' in control rats or after acute L-NAME treatment.
The selective blockers of the various vasoconstrictor systems were added in a cumulative and sequential manner in the following order: prazosin, losartan, AVP
antagonist, PD 145065 and SNP. The interval between administration was up to 15 min, where a new steady state MAP had been established before the blockade of the next vasoconstrictor system.
Experiment 2: Effects of I'D 145065 before or after NOS blockade After obtaining appropriate baseline steady-state levels of MAP, the effects of administration of losartan (30 mg/kg i.p., n=3, under 3U mg/kg i.p.
pentabarbital anesthetic) or I'D 145065 (10 mg/kg/min, i.v., n=6, conscious rats previously catheterized) on resting MAP and then on the L-NAME (100 mg/kg, i.p.)-induced pressor response were assessed in two ways. Administration of PD 145065 was done prior to giving L-NAME to assess the effect on the normal circulation as well as on the development of the hypertension, whereas the administration after L-NAME-hypertension was already present was used to assess reversibility of the pressor response.
Data Anal.~sis All data are expressed as a peak MAP lowering as a mean ~ S.D. Comparison of means between groups at each treatment level was done using a Student's T-test with the I3onferroni correction method, where appropriate.
Results Figure 1 illustrates the changes in steady state MAP responses following the sequential blockade of the vasoconstrictor systems in both the L-NAME (n=6) and saline control (n=6) groups. The steady state levels of MAP for saline and L-NAME-treated animals were 146 ~ 14 and 108 ~ 9 mmHg, respectively. The administration of large doses of prazosin~, losartan~ and (O-ET) VAVI' to antagonize the effects of 3 of the major vasoconstrictor systems lowered MAP by a similar extent in both the L-NAME (84 ~ 13 mmHg)- and saline (46 ~ 5 mmHg)-treated groups both on an absolute (delta MAP) t 't and proportional (% of range) basis (Table 1 below) and yet there remained the same pressor response in the L-NAME group compared to control.
Table 1 Saline L-NAME
Blocking went delta MAP % of range delta MAI' % of range prazosin 36 ~ 6 48 -!- 8 27 ~ 14* 25 ~ 10*
losartan 20 ~ 6 27 ~ 8 25 ~- 13 24 ~ 12 (O-ET)VAVP 21 ~ 11 37 ~- 15 19 -~ 13 15 ~ 9*
PD 145065 1 ~ 2 1 ~ 3 35 ~ 13* 39 ~ 24*
SNP 7~3 12~4 12~9 4~2 * denotes significant difference (p<0.05) compared to saline control The addition of PD 145065 to the saline-treated group following prazosin, losartan and (O-ET) VAVP administration did not significantly lower further the level of MAP (46 ~ 4 mmHg). In contrast, the addition of PD 145065 to the L-NAME-treated group under similar conditions dramatically lowered MAP from 84 ~ 13 mmHg to 46 ~ 7 mmHg.
The administration of SNP further lowered MAP to 39 ~ 3 mmHg across all treatment groups, revealing a small component of other systems in both treatment groups.
In Experiment 2, after obtaining appropriate baseline levels of MAP ( 100 ~ 15 mmHg), losartan treatment resulted in a lowering of MAP to 78 ~ 21 mmHg. In contrast, the administration of PD 145065 had no effect on the level of MAP ( 106 ~ 16 mmHg).
There was a marked difference in the L-NAME pressure profile between the saline- and PD
145065-treated group (Figure 2). The delta MAP responses 20 min after L-NAME
treatment in the saline and PD 145065 pre-treatment groups were 40 ~ 8 and 11 ~ 7 mmHg, respectively (p<0.05).
The above experiments demonstrate that the contribution of the sympathetic nervous system, renin-angiotensin system and vasopressin system are not enhanced in the acute L-NAME induced hypertensive state, yet there remains a markedly enhanced vasoconstrictor tone (=14096) compared to control. These studies also demonstrate that the pre-eminent mechanism of hypertension following acute NO synt.hase blockade is via endothelia-mediated vasoconstriction. This endothelia mechanism suggests that the prominent role of NO is to inhibit endothelia activity, likely by inhibiting its expression and release and not as a chronic direct acting vasodilator. Experiment 2 shows that pharmacological antagonism of the endothelia receptors does not change resting MAP, confirming previous studies that endothelia does not. function as a prominent vasoconstrictor In normal circulating states.
There are, however, certain conditions which may be considered physiologically 'normal' but in which local levels of endothelia cause vasoconstriction, such as erectile responses in males. Administration of an A/13 endothelia receptor antagonist in such circumstances will cause a desired local vasodilation and thus permit penile erection in an otherwise impotent male, and will decrease the potential for long term changes in vascular function and structure.
In situ Experimental Evidence for Endothelia as a 'Primer' Three points regarding the mechanisms of endothelia involvement in erectile dysfunction have been described hereinabove. There is now presented in situ evidence to demonstrate that enhanced levels of endothelia markedly 'sensitize' the pudenda( vascular bed to other vasoconstrictor systems. Stated another way, a slight enhancement of endothelia will synergistically enhance the impact of the sympathetic nervous system, i.e., a marked increase in vasoconstriction will result from even normal levels of sympathetic activation.
Vascular responses using the isolated perfusion of the pudendal vasculature preparation have been assessed. Figure 3 illustrates the dose response curve to the a-adrenoceptor agonist methoxamine (MXA) alone. Figure 4 illustrates the dose-response curve to endothelia alone. Table 2 represents the changes in perfusion pressure when low, sub-pressor doses of endothelia + MXA are given in comparision to MXA alone.
These findings demonstrate that the MXA concentration-response (perfusion pressure) relationship was shifted to lower concentrations by more than 10-fold, i.e., when low doses of endothelia and MXA which alone are sub-pressor were combined, the effect was a pronounced increase in vascular resistance. 'these findings demonstrate that low level endothelia stimulation in the penile vasculature will result in synergism when a-adrenergic receptors are activated.
Methods Animals Male Wistar rats (400-500 g), obtained from Charles River Laboratories (Montreal, Quebec, Canada), were housed individually under conditions of a 12 h light/12 h dark cycle (temperature of 22-24°C), and were provided with Purina Rodent Chow and tap water ad libitum for at least two days before starting any experiment.
Pudendal Perfusion Preparation The rats were anaesthetized with sodium pentabarbital (60 mg/1cg i.p.) and the lower abdominal aorta was exposed through a mid-line incision. 'The isolation of the pudendal vasculature was developed by sequential ligation of all branches of the abdominal aorta not directly supplying the pudendal vasculature. The following arteries were dissected free and ligated: iliaca, femoralis, poplitea, glutea cranial, umbilicalis, epigastria caudal, pudenda external, glutea caudal, obturatoria, circumflexa femoris lateral, circumflexa femoris medial. After heparinization (1000 U/kg), the abdominal aorta was cannulated with a smooth, blunted 19-gauge needle. The arterial catheter was placed caudad into the aorta and the vena cava was cut and vented freely through the widely open abdominal cavity. rl'he tip of the needle was advanced down the aorta to the iliac bifurcation and sutured in place. Flow of perfusate (0.5 mL/kg body weight/min) through the abdominal aorta was started immediately after transection, with sharp surgical scissors, of the abdominal aorta, inferior vena cava, spinal cord and all tissue 1 cm lateral to the spinal cord between T3 and T~ (Figure 2). The perfusate was infused for 10 min, to flush the penile vasculature of blood, before starting any experiment.
The perfusate consisted of dextran (15%, average molecular weight: 71,400 Da, Sigma, St. Louis, MO, U.S.A.) in Tyrode's solution (pH 7.4), which was aerated with 95%
Oz and 5% CO2. The composition of the Tyrode's solution was I~C1 20, CaCy2H20 32.3, MgClz~6H20 5.1, NaHzP04~2H20 6.2, NaI-IC03 100, glucose 100, and NaCI
mg per 100 mL fluid. The perfusate was held in a reservoir, and passed through a bubble trappin~mixing chamber and heating bath by an injection port located prior to the bubble trap for the introduction of pharmacological agents. An in-line peristaltic pump was used to establish flow at 0.5 mI/k~min (Minipuls 2, Gilson Medical Elec., Ine., Middleton, WI, U.S.A.). Added pharmacological agents, methoxamine (MXA) and sodium nitroprusside (SNP), were delivered by a syringe pump (Harvard Apparatus Infusion/Withdrawal Pump, Minis, MA, U.S.A.). A servo-controlled heat chamber served to maintain rectal temperature at 36-38°C.
Table 2: A comparision of the perfusion pressure responses in control and endothelia sub-pressor treated rats to the a,-adrenoceptor agonist methoxamine.
(D Perfusion Pressure (mmHg)) [methoxamine ~eg/ml Control Endothelia sub-pressor 0.1 0 0 0.25 0 34 _+2 0.5 0 93 _+ 30 1.0 4 + 1 168_+ 16 2.0 1 1 + 2 4.0 36 + 1 1 -8.0 67 + 24 -Values are expressed as group mean + S.D., n=6 for control, n=4 for endothelia sub-pressor.
Experiment: Effects of Endothelia Antagonists on Elockade of Apomorphine-induced Erections Lt is well known that NOS blockers (e.g., L-NAME) inhibit erectile response acutely. According to our novel understanding of normal vascular biology as described herein, we proposed that the mechanism of L-NAME-induced erectile dysfunction, at least acutely, is dependent on the activation of endothelia (ET)-mediated vasoconstriction, and can thus be reversed with an ET antagonist. This was confirmed experimentally as described below.
Methods Using the well-established apomorphine (APO)-induced erection model (apomorphine 80 ~,g/kg, administered subcutaneously), we counted the erections per 30 min interval in adult Wistar rats, per the protocol of Heaton, J.P.W., et al.
(1991)(43).
Rats were pretested with apomorphine alone to confirm and quantify normal erectile response(control Groups A and B). Rats were then treated with L-NAME ( 100 m~kg, administered intraperitoneally) alone, acutely (at < 1 h) and at 3 h; or the combination of ET,~ antagonist (PD 145065, 5 m~lcg/min, continuous intravenous infusion) + L-NAME.
Results Data represent mean number of erections ~ S.D. in the various different treatment groups. L-NAME alone blocked erection. Addition of the ET antagonist completely reversed acute L-NAME-induced decrease in erections, resulting in normal incidence of apomorphine-induced erections.
Group-A Group -B L-NAME-acute PD 145065 + L-NAME-3 h (control) (control) L-NAME
3.0 ~ 1.31 2.5 ~0.58 1.4 ~ 0.74** 2.5 ~ 0.58 3.7 ~ 1.38 ** indicates significant difference from control (p<0.01).
Conclusions The mechanism of decreased erectile function following acute L-NAME involves increased endothelin-mediated vasoconstriction.
By this experiment in combination with the foregoing, the inventors provide proof of concept of their novel model of normal vascular biology and of the use of endothelin antagonists in down regulating local endothelin-mediated vasoconstrictor tone and vascular growth activity in a patient independently of any normal or abnormal systemic physiology.
All scientific publications cited herein are hereby incorporated by reference.
Although this invention is described in detail with reference to preferred embodiments thereof, these embodiments, like the experiments described herein, are offered to illustrate but not to limit the invention. It is possible to make other embodiments that employ the principles of the invention and that fall within its spirit and scope as defined by the claims appended hereto.
" r . , References 1. Garg, U.C., and Hassid, A., J. ~3iol. (:hem. 266: 9-12 ( 1991 ).
2. Garg, U.C., and Hassid, A., J. Clin. Invest. 83: 1774-1777 (1989).
3. Palmer, R.M.J., et al., Nature 327: 524-526 (1987).
4. Assender, J.W., et al., J. Cardiovasc. 1'harmacol. 17(Suppl.3):
S 104-S 107 ( 1991 ).
FIELD OF THE INVENTION
')'his application is a continuation-in-part of U.S.S.N. 08/615,659 filed March 13, 1996, the contents of which are hereby incorporated herein by reference.
This invention relates to methods fo.r down-regulating local endothelia-mediated vasoconstrictor and/or vascular growth activity in "apparently" normal physiological canditions in order to re-establish normal control in specific regions of the circulation which demonstrate pathophysiology. More particularly this invention relates to the administration of agents which antagonize the expression or activity of endothelia for the treatment of abnormalities of specific regions of the vasculature such as in erectile dysfunction in male patients.
BACKGROUND OF INVENTION
Endothelins were first described in 1988 and have been shown to be powerful vasoconstrictors, predominantly found in the vascular endothelium. and, since that time, numerous endothelia antagonists and pharmaceutically acceptable salts thereof have been identified and can be obtained commercially (e.g., Sigma, American Peptides).
Attention is also directed to U.S. Patents No. 5,284,828 issued 8 February 1994 to Hemmi et al., No. 5,378,715 issued 3 January 1995 to Stein et al. and No. 5,382,569 issued 17 January 1995 to Cody et u1., which describe in detail the chemical structures of various endothelia antagonists, and to U.S. Patent No. 5,338,726 issued 16 August 1994 to Shinosaki et al., which describes the chemical structure of endothelia converting enzyme inhibitors, the disclosures of which are incorporated herein by reference. To date, however, antagonists of endothelia have not been approved for therapeutic use, although a number of investigators have postulated that endothelia antagonists could be used for conditions ranging from renal failure, endotoxic shock, asthma, angina, or diabetes to pulmonary hypertension and possibly other indications.
Under normal physiological conditions, endothelia can be found in almost all parts of the circulation at very low levels. In general, in the normal rodent circulation endothelia (ET) is not found in elevated quantities and appears to have minimal effect in the normal regulation of vascular tone, i.e., there is no appreciable decrease in blood pressure when an endothelia antagonist is administered by injection in normal circulation.
Further, at present there does not appear to be any evidence suggesting that E'r plays a physiological role even in a small portion of the circulation under normal conditions in experimental models. However, it is likely that the circulation may appear normal when in fact a specific region of the circulation reveals pathophysiological changes, such as occurs with erectile dysfunction. Penile erection demands specific local vasodilation and/or inhibition of local vasoconstrictor mechanisms. It is not surprising that findings of elevated levels of endothelia in the blood are not widespread, as the regulation of ET action indicates a release preferentially towards the smooth muscle side, away from the circulation. In addition, it is highly improbable that there would be increased ET found in the circulation resulting from increased activity in a small portion of the circulation. ET is known to have a very short half-life.
It is widely known that administration of nitric oxide (NO) can provoke powerful vasodilator responses. The chronic role of nitric oxide synthase (NOS) as a vasodilator has only been inferred by indirect means, i.e., by removal of the NOS activity.
Endogenously, there is much more redundancy in control of vasodilatation. For example, vasodilation can be induced by acetylcholine, bradykinin, adenosine triphosphate (ATP), histamine, vasoactive intestinal polypeptide (VIP), and leukotrienes, amongst others. The actions of these endogenous modulators have been shown to be dependent on the presence of the endothelium, an effect likely mediated by endothelial derived relaxing factor /NO
(EDRF/NO) (1,2,3). Other vasodilator mechanisms exist which are not endothelium dependent, such as ~i2-adrenergic, anal natriuretic peptide (ANP) and certain prostaglandins. The actions of NO appear to be mostly cGMP-mediated via guanylate cyclase activation, although other mechanisms have been suggested. Garg and Hassid ( 1, 2) and others (4,5) demonstrated a difference in the effects of NO-generating vasodilator agents in inhibiting vascular smooth muscle cell growth in culture; however, it is clear that NO can act not only as a vasodilator but also to inhibit vascular growth responses in a number of conditions (6).
In the last several years a large number of studies has demonstrated that decreased NO production using inhibitors of NO synthase (e.g., N"-vitro-L-arginine-methyl ester or L-NAME) produces dose-dependent hypertension (i.e., L-arginine reversible, and which correlates with decreased cyclic guanosine monophosphate (cGMP)) (7,8,9). Data from Schiffrin's (4,10) and Morton's ( 11 ) groups demonstrate that prolonged high dose L-NAME hypertension is associated with hypertrophic changes in the mesenteric vasculature ( 1 media thickness and t media/lumen ratio). Interestingly, Schiffrin's group found that the degree of change in vascular structure was less marked than in other models (2I<1C) with equivalent hypertension and of a similar duration. rl'aken together with the findings of NO development of cardiac hypertrophy and slower vascular changes, current evidence indicates that L-NAME hypertension is quite different from other models.
Further, although these findings could suggest a rote for NO as a modulator of vascular structure, our recent findings suggest that NO may play a more important inhibitory role in suppressing the activity of the endothelia vasoconstrictor system. The concept of NO
suppression of ET expression is further supported by evidence both from Luscher's group in vitro and from the Clozel group (12) in vivo showing that there is increased release of ET
from endothelial cells afl.~~',_1y0~ _blockage. These data suggest that exogenous administration of NO synthase antagonists produces a condition wherein the lack of NO
appears to be a modulator of ET expression and release. Recent findings, in particular from Schiffrin's group ( 13,14), in deoxycorticosterone acetate (DOCA)-salt hypertension point to a trophic role for endogenous endothelia in the development of vascular structural changes. They found that there is increased ET-1 gene expression and immunoreactivity in blood vessels, but not in the plasma, of DOCA-salt hypertensive rats, whereas renin angiotensin system (RAS) activity was decreased. There was a substantial development of vascular hypertrophy in the DOCA-salt model which was markedly attenuated by treatment with an ETp/ETB receptor antagonist. The concept that ET-1 is a vascular trophic factor is further supported by findings in studies with cultured vascular smooth muscle cells showing that addition of endothelia produces a mitogenic response ( 15), as well as findings in other in vivo studies indicating a role in structural changes associated with pulmonary hypertension ( 1 b). ET-1 is approximately 100 times more potent as a vasoconstrictor than Ang II or catecholamines. Interestingly, in the culture studies, although the maximal growth response to ET-1 was less than half of that for Ang II, the combination of ET-1 plus Ang II provoked a greater mitogenic response than either peptide alone. We are not aware of any studies that have assessed the in vivo cardiovascular growth responses to direct endothelia infusion.
An important aspect of the invention derives from the development of a concept which reveals an interrelationship between NO activity and endothelia vasoconstrictor activity, in vivo: specifically, that NO acts primarily as a chronic inhibitor of endothelin-mediated vasoconstriction, and less as a chronic vasodilator. Accordingly, it is proposed that endothelia plays a role in disease conditions associated with impaired NO
synthesis, particularly if the pathophysiology is restricted to a specific portion of the circulation; i.e., if the entire circulation were altered, numerous compensatory changes in neurohumoral systems would also occur.
Our hypothesis is that if NO synthesis is inhibited, a significant increase in mean arterial pressure (MAP) is the result of increased endothelia release and this MAP increase can be eliminated by administration of an endothelia antagonist. It is apparent, therefore, that administration of an endothelia antagonist in physiological conditions where NO
production is inhibited will result in vasodilation ONLY in the regions which have upregulated ET activity consequent, in part, to a down regulation of local NO
production.
Physiological conditions where NO production is inhibited in a local circulation, such as male erectile dysfunction, indicate that suppression of endothelia activity would offer an effective treatment.
Based on the understanding that a significant portion of the underlying problem in clinical erectile function relates to "vascular" mechanisms, much of the current state-of-the-art research involves determining the contribution that the different vascular effector control systems make in normal and pathophysiological states. There is substantial understanding of the hemodynamic events that lead to an erection, and yet the quantitative roles of each of the neuroeffector, humoral and local systems in these events remain poorly described. Since 1990, nitric oxide (NO) has been considered the primary non-adrenergic non-cholinergic neurotransmitter in the penis and has been presumed to be the primary mediator of corporal relaxation during erection.
The issue of "impotence" was discussed at the National Institutes of Health (NIH) in Washington in December 1992 (defined as "a pattern of persistent or recurrent inability to develop or maintain an erection of sufficient rigidity for successful coitus") and has clearly been identified as having a wide range of causative or associated factors. The Massachusetts Male Aging Study (MASS) has provided us with an updated view of the epidemiology of erectile dysfunction although there seem to be some unchangeable truths -it is accepted that the prevalence of impotence increases with age (IGnsey, 1948) (17).
Complete erectile dysfunction (ED) increases from 5 to 15% between 40 and 70 years of age, Feldman, 1994 ( 18). ED has been shown to be "directly correlated with heart disease, hypertension, diabetes, associated medications, indices of anger and depression, and inversely with serum dehydroepiandosterone, high density lipoprotein, cholesterol and an index of dominant personality."
It is now estimated that in North America there are more than 30,000,000 men with ED, a significant increase from the figure of 10,000,000 used just 10 years ago (Shabsigh et al., 1988 (19); Whitehead, 1988 (20); Furlow, 1985 (21)). From these figures it is also reasonable to estimate that as many as three million Canadian men may have a degree of ED. The direct cost of treating impotence is impressive. Reliable figures for 1985 show that the cost of treating impotence exceeded 146 million dollars in the United States in that year alone (National Center for Health Statistics) and this number is just the estimated market size for one type of injectable therapy. The secondary effects and indirect costs associated with erectile dysfunction would suggest that impotence and sexual dysfunction are medical icebergs. The consequences of sexual dysfunction may be seen in strains on the host relationship potentially leading to marital breakdown, violence, work related sequelae, deviant sexual behavior, and impacts on children, when present, that can carry the damage into a new generation of unwanted behaviors. If ED underlies even a small but significant percentage of marital and family breakdown, then it adds vastly to the social and economic burden in society. The pragmatic issue is that large numbers of men are now being treated for ED and most of the treatments are fairly blunt instruments (intracavernosal injection (ICI) of mixed vasoactive compounds, penile prosthesis insertion) with significant cost and complications (ICI: pain, priapism, dislike of the technique; prostheses: reoperation, infection, distortion of body image).
As a medical and scientific problem, ED gained greatly in stature when Rajfer et al.
(1992) (22) published their information linlting nitric oxide (NO) with normal erectile function. It was an interesting coincidence that NO became "Molecule of the Year" that same year as a result of the accumulated and established work in other vascular systems.
This heralded a new maturity in the study of ED - suddenly the principles of normal vascular biology (NVB) became accepted as the underpinnings of erectile physiology.
The Physiological Basis of Penile Erection The stimulus to erection is central and neural in origin. A fully functional penile erection requires coordinated input from various levels of the central nervous system and at least three sets of peripheral nerves (thoracolumbar sympathetic, saccral parasympathetic, and pelvic somatic). Adrenergic, non-adrenergic and non-adrenergic non-cholinergic neurotransmitter systems of importance have been identified in the cavernous tissue (Saenz de rhejada, 1988) (23). An excellent account of the neural processes (without specific roles) involved in the production of a penile erection can be found in the review by deGroat and Steers (1988) (24).
A penile erection is dependent upon the integration of anatomic, vascular (hydraulic; arterial and venous), endocrine, neurologic and hormonal mechanisms. The erectile components of the penis are the corpora cavernosa and the corpus spongiosum.
The latter contributes little to the rigidity of the penis when erect. The corpora cavernosa are paired cylinders that are firmly and separately anchored to the inferior pubic rami at their proximal roots, where they are covered by striated muscle (ischiocavernosus), become joined in the proximal pendulous shaft and fenestrated (i.e., functionally connected) distally. There is usually one supplying end-artery per cavernosal body, from the internal iliac artery, that branches to become the deep penile artery which has at least two types of branches within the cavernosa: The venous drainage of the corpora is through the intermediate system for the distal cavernosa and plans and through the deep system for the remaining cavernosae. 'The critical venous channels are the subtunical veins, which empty through emissary veins that pass through the tunica and drain into the deep dorsal vein. It is the emissary veins that are compressed during erection and permit the "locked" state of veno-occlusion.
It is well established that, for erection, neurally mediated (autonomic) vasodilation of the penile arterial blood vessel and the trabecular meshwork takes place (Lue et al. , 1987) (25) permitting extra blood flow into the cavernous bodies of the penis.
The expanding intracorporal volume traps the effluent veins that lie between the erectile tissue and the surrounding, relatively inelastic, fibrous tunica albuginea. The outflow capacity is thereby decreased and entrapment of blood ensues, resulting in the transformation of the flaccid penis into its erect state (Juenemann et al., 1986 (26); Lue et al., 1987 (25); Lue et rtl., 1983 (27); Weiss, 1980 (28)). Inflow arterial tone is of absolute importance in this process, although adequate driving blood pressure (BP) is a necessary factor.
The converse, detumescence, is mediated by the sympathetic nervous system (Saenz de Tejada, 1988 (23); Juenemann et al., 1989 (29)) and is dependent on the metabolic viability of cells within the erectile tissue. A maximal direct pharmacological vasodilator stimulus may b not produce an erection in a penis driven by the high sympathetic nervous system activity state induced by fear. Thus, it is not surprising that alterations in blood flow and vascular dynamics, whether produced by decreased cardiac output, reFlex sympathetic hyperactivity, atherosclerosis, untreated hypertension, antihypertensive medication or, as herein proposed, increased local endothelia-mediated vasoconstriction, can produce profound effects on the ability of the flaccid penis to be transformed into the erect state.
Penile control systems The known control systems for erection are conventionally described under the headings: adrenergic, cholinergic and non-adrenergic non-cholinergic (NANC).
Adrenergic IO nerve fibers and high concentrations of norepinephrine can be found in the corpora (Melman and Henry, 1979 (30); Benson et al., 1980 (31 )) and the contractile properties of phenylephrine are established unequivocally (Hedlund et al., 1984 (32); Christ et al., 1990 (33)) with post-synaptic al effects acting directly and pre-synaptic a2 modulation.
Previously, parasympathetic nerves were thought to be the nerves responsible for erection (Wagner et al., 1980 (34)), although the in vitro effects from acetylcholine (ACh) were varied in early experiments (Adaikan et al., 1983 (35); Hedlund et al., 1985 (32)). Further, simple intracorporal injection of acetylcholine does not cause erection and atropine does not block it (Wagner et al., 1980) (34). Thus, cholinergic nerves are described as modulators of neural function. Accordingly, NANC innervation, as the pre-eminent player in erectogenesis, has received intense scrutiny and the current thinking is that nitric oxide has replaced VIP as the prime vasodilator of this system in the penis. rI his view was first published by Ignarro et al. (36) and has been re-stated many times since. Not surprisingly, a variety of other NANC systems have also been shown to play a role in erectile function, including vasoactive intestinal polypeptide (VIP) (Gu et al., 1983 (37) &.4 (38); Willis et al., 1983 (39)), calcitonin gene related peptide (CGRP) (Stief, 1990) (40) and the prostaglandins (Hedlund and Andersson, 19$5) (41). The terms that have been used to describe the neuroeffector systems and the roles they play provide an historic basis for descriptions of penile systems but have not removed the confusion that is found in the more than 100 relevant papers that have been published since 1990 on neural regulation.
It is without doubt that penile erections occur when arterial dilation and smooth muscle relaxation take place. The penis is an ideal vascular bed to consider in terms of the physiological opposition of neural effector systems involved in both relaxation and contraction i.e the penis is one of only a small handful of special circulations with dual vasoconstrictor and vasodilator neural control systems. ?'o fully characterize the penile control systems, a greater understanding of the countervailing systems both in a clinical and an experimental setting is required in order to elucidate the critical balance and interdependence that are essential for normal function.
As described, in order for penile tumescence to occur, the pudendal vascular bed must vasodilate to shunt blood flow to the cavernosal tissue. Normal vascular beds have a balance of vasodilators and vasoconstrictors regulating the level of vascular tone.
Upsetting of this balance can lead to an enhanced chronic vasoconstrictor response.
Chronic erectile dysfunction creates a situation where the penile vascular bed has seen chronic low oxygen partial pressures pOz. Low p02 has been shown to decrease the activity of NO synthase and hence NO production. Further, it has also been shown, in rats, that the activity of the NO synthase enzyme decays with age. Both of these concepts in combination with our novel findings indicate a key role for enhanced endothelin-mediated vasoconstriction. Once enhanced endothelin occurs, there are three levels of mechanisms that will sustain the erectile dysfunction: (l) enhanced vasoconstriction in the penile vascular bed occurs, making it more 'difficult' for the vasodilators to shunt blood to the penis to facilitate cavernosal filling (this is also a positive feedback loop with respect to NO synthase since less blood flow will maintain low p01 values); (ii) endothelin has been shown in vitro and in vivo to promote cardiovascular growth processes. This could lead to a structural change where blood vessels grow and encroach on the lumen, leading to increased resistance due to a structural mechanism (as opposed to chronic vasoconstriction); and (iii) enhanced endothelin may act as a 'primer' for other vasoconstrictor systems (renin-angiotensin system and sympathetic nervous system) which additionally act as trophic factors (i.e., the endothelin may prime the vascular bed such that Ang II, for example, will promote growth at doses that by themselves would not normally induce growth processes).
In summary, an upregulation of endothelin actions occurs when the production of NO is inhibited. This chronic enhanced endothelin, we propose, will be involved in mediating the changes leading to erectile dysfunction. Acutely, there will be enhanced vasoconstriction via the endothelium (endothelin) and, in the longer term, endothelin-mediated growth responses in the vascular tissue. The penile vascular tissue would, therefore, go through a structural change such that it. would become more and more difficult to cause vasodilation with the progression of encroachment into the lumen of the vessels leading to the penis, as well as in the corpus cavernosal tissue itself.
There are several approaches that lead to the down regulation of the activity of endothelia, namely (a) peptide antagonists such as PD 145065 (Parke Davis), (b) non-peptide antagonists such as bosentan (Hoffman-LaRoche) (42), (c) inhibitors of endothelia converting enzyme, such as for example phosphoramidon (i.e., blocking production of endothelia) and (d) antisense oligonucleotides which specifically block the translation of the endothelia protein at the genetic level, i.e., disrupt the normal cycle of evems with preproendothelin mRNA.
BRIEF STATEMENT OF INVENTION
Thus, it is an object of the present invention to provide a method for treating physiological conditions in which NO production is at least partially inhibited, such as, but not limited to, erectile dysfunction (ED).
Another object of this invention is to provide compositions of matter for the treatment of physiological conditions in which NO production is at least partially inhibited.
By one aspect of this invention, there is provided a method for treating physiological conditions in which NO production is at least partially inhibited, comprising administering to a patient in need thereof an effective amount of an agent which will antagonize the actions of endothelia (antisense to ET-mRNA, or ET antagonists, ECE
antagonists).
By another aspect of this invention, there is provided a composition for use in the treatment of physiological conditions in which NO production is at least partially inhibited, comprising an effective amount of an endothelia antagonist or pharmaceutically acceptable salt thereof in admixture with a pharmaceutically acceptable carrier therefor.
In a preferred aspect, said physiological condition is erect.ile disfunction.
BRIEF DESCRIPTION OF DRAWINGS
Figure 1 is a block diagram illustrating MAP response with vasoconstrictor blockade (n = 8, 8);
Figure 2a is a graph illustrating MAP response with L-NAME pretreated with losarfan or PD 145065, (n = 6, 6);
Figure 2b is a graph illustrating MA1' response after treatment with L-NAME
followed by 1'D145065;
Figure 3 is a graph illustrating the cumulative dose response to methoxamine, n =
6; and Figure 4 is a graph illustrating tine cumulative dose response to endothelin, n = 4.
DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS
It is known that, in vivo, several systems contribute to vascular tone and mean arterial pressure (MAP). These systems include the sympathetic nervous system (SNS), renin-angiotension system and the vasopressin system. As described in more detail hereinafter, the contribution of each of these different systems to an experimentally induced pressure increase of 30-40% in rats as a result of NO synthase (NOS) inhibition with N"-vitro-L-arginine-methyl ester (L-NAME, Sigma Chemicals) has been assessed. If NO production is inhibited, a significant increase in MAP must be the result of endothelin release, since this MAP increase is eliminated when an endothelia antagonist is added.
Thus, it has been established that NO acts to chronically (locally) down-regulate the release of endothelia, not as a chronic direct acting vasodilator. 'The contribution of endothelia induced vasoconstriction to L-NAME hypertension was assessed by administering an ET,,~ETB receptor antagonist such as PD 145065 (Parke Davis Pharmaceuticals) in a pharmaceutically acceptable carrier therefor, both before and after NO synthase inhibitor "inhibition". Suitable carriers include water and isotonic dimethyl sulfoxide (DMSO). PD145065 is a peptide and hence not readily bioavailable by oral administration. Non-peptide receptor antagonists would be better choices for oral administration. PD 145065 may be effectively administered by intravenous administration.
It will be appreciated that, in the experiments described below, an ETA/ETB
receptor antagonist was used in order to control for any transient vasodilation which might occur via an ET8 receptor, and which would skew the estimation of involvement in hypertension following NO synthase blockade. It is believed, however, that ETA or ETB
receptor antagonists alone would also, at least in part, suppress the endothelia induced vasoconstriction.
ETA and ETB antagonists are available commercially from various sources such as American Peptide Company Inc. and include:
.a ETA
NAME FORMULA CAT NO.
Endothelia Antagonist c(DTrp-DAsp-Pro-DVaI-Leu) (SEQ ID NO: 1 ) 88-2-10 Endothelia Receptor c(DGIu-Ala-Allo-Dlle-Leu-DTrp) (SEQ ID NO: 2) 88-2-20 Antagonist (BE18257B) Endothelia Antagonist (JKC-301 ) c(Dlle-Leu-DTrp-DAsp-Pro) (SEQ ID NO: 3) 88-2-Endothelia Antagonist (JKC-302) c(DVaI-Leu-DTrp-DSer-Pro) (SEQ ID NO: 4) 88-2-Endothelia Antagonist (BQ-610) (N,N-hexamethylene)carbamoyl-Leu-DTrp(CHO)-DTrp (SEQ ID NO: 5) 88-2-32 Endothelia Receptor Antagonist c(DGIu-Ala-DVaI-Leu-DTrp) (SEQ ID NO: 6) 88-2-(W-7338A) EIB
NAME FORMULA CAT NO.
[Cys11,Cys 15] Endothelia-1 c(DGIu-Ala-DVaI-Leu-DTrp) (SEQ ID NO: 7) 88-2-41 (8-21 ), (1 RL-1038) [A1a11,15] Endothelia-1 (6-21), Ac-Leu-Met-Asp-Lys-Glu-Ala-Tyr-Phe-N-Acetyl Ala-His-Leu-Asp-Ile-Ile-Trp (SEQ ID NO: 8) 88-2-42 N-Suc-[GIu9,Ala11,15]Endothelia- Suc-Asp-Glu-Glu-Ala-Val-Tyr-Phe- 88-2-50 1, (8-21 ), (LRL-1620) Ala-His-Leu-Asp-Ile-Ile-Trp (SEQ ID NO: 9) Methods Animals Male Sprague-Dawley rats (325-400g) obtained from Charles River Laboratories (Montreal, Quebec, Canada) were housed individually under conditions of a 12 h light/12 h dark cycle, with room temperature at 22-24°C, and were provided with Purina Rodent Chow and tap water ad libitum for at least 2 days before any experiments were started.
Measurement of MAP and Short Actin, DrueAdministration The surgical method was based on the technique of Thompson et al.
(Hypertension 20: 809-815 ( 1992)). In brief, rats were anesthetized with ketamine/xylazine (70/5 mg/kg i.p.), and the descending aorta distal to the kidneys was catheterized with small bore TEFLON~ tubing (0.012-in. i.d., o.d. 30 gauge, Cole-farmer, Laval, Quebec, Canada) inserted into vinyl tubing (0.02-in. i.d., 0.060-in. o.d., 23 gauge). The inferior vena cava was also catheterized distal to the kidneys with small bore rl'EFLONO tubing (0.012-in.
i.d., o.d. 30 gauge, Cole Parmer). The catheters were filled with heparinized saline ( 10 IU/mL) and held in place by a small amount of cyanoacrylate tissue glue at the puncture site. The catheters were tunneled subcutaneously and exteriorized at the back of the neck and sutured in place. Two days after surgery, MAf could be recorded (Narco Physiograph, E&I Instruments, Houston, TX or MacLab Data Acquisition System, ADInstruments, Milford, MA, U.S.A.). After connection, an equilibration period of approximately 30 min was allowed for the determination of the steady state level of MAP before any recording began. Baseline MAP was determined from mean readings over 5 min, taken from each rat at I5 min intervals for at least 1 h prior to the start of any experiment.
After obtaining a baseline MAP, the cumulative/sequential vasoconstrictor blockade was started.
MAP
values are expressed as an average MAP over 2-3 min following the establishment of a new steady state (i.e., MAf is no longer changing).
Experiment I : Cumulative vasoconstrictor blockade following acute NO
inhibition NOS was inhibited by a single i.p. injection of N''-vitro-L-arginine-methyl ester (L-NAME, Sigma, 100 mg/kg; 100 mg/mL 0.9% sterile saline solution, Baxter Corp., Toronto, Ontario, Canada). The ai-adrenoceptor antagonist prazosin~ (Sigma Chemical Company, St. Louis, MO, U.S.A.) at a dose of 1 mg/kg (in 0.9% saline and 5% ethanol [vol/vol], total volume 1 ml~kg) was used to block the majority of the SNS induced peripheral vasoconstriction. The non-peptide AT, receptor antagonist losartan~ (Dupont-Merck, 30 mg/kg i.p.) was used to block the effects of Ar<g II. The ';/V2 receptor antagonist [(3-mercapto-(3, [3-cyclopenta-methylenepropionyl, O-Et-Tyre-Val4-ArgB]-vasopressin (AVP) (20 ~eg/lcg/min i.v., Sigma) was utilized to block the effects of vasopressin.
The effects of the endothelia vasoconstrictor system, via ETA and ETB receptors, were blocked with a commercially available endothelia antagonist fD 145065 (100 mg/k~min i.v., bolus, donated by Parke-Davis Pharmaceuticals). Each rat in the study received all of the aforementioned vasoconstrictor antagonists (i.e., a cumulativeJsequential blockade). The addition of sodium nitroprusside (SNP) (200 ~cg/kg i.v. 0.3 c.c. bolus, Sigma) was used to transiently lower MAP to the level of minimum vascular resistance across all treatment groups (i.e., where the level of MAP becomes predominantly dependent on cardiac output at minimum vascular resistance; MAl',",;" = CO x'rl'1~";"). Not surprisingly, this value was found to be similar across all treatment groups and enabled the calculation of the total range of MAP pressure lowering (MAI~a"gp=MAl'-MAP",;"). As well, the addition of SN1' reveals the activity of 'other' vasoconstrictor systems that might not have been accounted for but may be important in contributing to the level of MAl' in control rats or after acute L-NAME treatment.
The selective blockers of the various vasoconstrictor systems were added in a cumulative and sequential manner in the following order: prazosin, losartan, AVP
antagonist, PD 145065 and SNP. The interval between administration was up to 15 min, where a new steady state MAP had been established before the blockade of the next vasoconstrictor system.
Experiment 2: Effects of I'D 145065 before or after NOS blockade After obtaining appropriate baseline steady-state levels of MAP, the effects of administration of losartan (30 mg/kg i.p., n=3, under 3U mg/kg i.p.
pentabarbital anesthetic) or I'D 145065 (10 mg/kg/min, i.v., n=6, conscious rats previously catheterized) on resting MAP and then on the L-NAME (100 mg/kg, i.p.)-induced pressor response were assessed in two ways. Administration of PD 145065 was done prior to giving L-NAME to assess the effect on the normal circulation as well as on the development of the hypertension, whereas the administration after L-NAME-hypertension was already present was used to assess reversibility of the pressor response.
Data Anal.~sis All data are expressed as a peak MAP lowering as a mean ~ S.D. Comparison of means between groups at each treatment level was done using a Student's T-test with the I3onferroni correction method, where appropriate.
Results Figure 1 illustrates the changes in steady state MAP responses following the sequential blockade of the vasoconstrictor systems in both the L-NAME (n=6) and saline control (n=6) groups. The steady state levels of MAP for saline and L-NAME-treated animals were 146 ~ 14 and 108 ~ 9 mmHg, respectively. The administration of large doses of prazosin~, losartan~ and (O-ET) VAVI' to antagonize the effects of 3 of the major vasoconstrictor systems lowered MAP by a similar extent in both the L-NAME (84 ~ 13 mmHg)- and saline (46 ~ 5 mmHg)-treated groups both on an absolute (delta MAP) t 't and proportional (% of range) basis (Table 1 below) and yet there remained the same pressor response in the L-NAME group compared to control.
Table 1 Saline L-NAME
Blocking went delta MAP % of range delta MAI' % of range prazosin 36 ~ 6 48 -!- 8 27 ~ 14* 25 ~ 10*
losartan 20 ~ 6 27 ~ 8 25 ~- 13 24 ~ 12 (O-ET)VAVP 21 ~ 11 37 ~- 15 19 -~ 13 15 ~ 9*
PD 145065 1 ~ 2 1 ~ 3 35 ~ 13* 39 ~ 24*
SNP 7~3 12~4 12~9 4~2 * denotes significant difference (p<0.05) compared to saline control The addition of PD 145065 to the saline-treated group following prazosin, losartan and (O-ET) VAVP administration did not significantly lower further the level of MAP (46 ~ 4 mmHg). In contrast, the addition of PD 145065 to the L-NAME-treated group under similar conditions dramatically lowered MAP from 84 ~ 13 mmHg to 46 ~ 7 mmHg.
The administration of SNP further lowered MAP to 39 ~ 3 mmHg across all treatment groups, revealing a small component of other systems in both treatment groups.
In Experiment 2, after obtaining appropriate baseline levels of MAP ( 100 ~ 15 mmHg), losartan treatment resulted in a lowering of MAP to 78 ~ 21 mmHg. In contrast, the administration of PD 145065 had no effect on the level of MAP ( 106 ~ 16 mmHg).
There was a marked difference in the L-NAME pressure profile between the saline- and PD
145065-treated group (Figure 2). The delta MAP responses 20 min after L-NAME
treatment in the saline and PD 145065 pre-treatment groups were 40 ~ 8 and 11 ~ 7 mmHg, respectively (p<0.05).
The above experiments demonstrate that the contribution of the sympathetic nervous system, renin-angiotensin system and vasopressin system are not enhanced in the acute L-NAME induced hypertensive state, yet there remains a markedly enhanced vasoconstrictor tone (=14096) compared to control. These studies also demonstrate that the pre-eminent mechanism of hypertension following acute NO synt.hase blockade is via endothelia-mediated vasoconstriction. This endothelia mechanism suggests that the prominent role of NO is to inhibit endothelia activity, likely by inhibiting its expression and release and not as a chronic direct acting vasodilator. Experiment 2 shows that pharmacological antagonism of the endothelia receptors does not change resting MAP, confirming previous studies that endothelia does not. function as a prominent vasoconstrictor In normal circulating states.
There are, however, certain conditions which may be considered physiologically 'normal' but in which local levels of endothelia cause vasoconstriction, such as erectile responses in males. Administration of an A/13 endothelia receptor antagonist in such circumstances will cause a desired local vasodilation and thus permit penile erection in an otherwise impotent male, and will decrease the potential for long term changes in vascular function and structure.
In situ Experimental Evidence for Endothelia as a 'Primer' Three points regarding the mechanisms of endothelia involvement in erectile dysfunction have been described hereinabove. There is now presented in situ evidence to demonstrate that enhanced levels of endothelia markedly 'sensitize' the pudenda( vascular bed to other vasoconstrictor systems. Stated another way, a slight enhancement of endothelia will synergistically enhance the impact of the sympathetic nervous system, i.e., a marked increase in vasoconstriction will result from even normal levels of sympathetic activation.
Vascular responses using the isolated perfusion of the pudendal vasculature preparation have been assessed. Figure 3 illustrates the dose response curve to the a-adrenoceptor agonist methoxamine (MXA) alone. Figure 4 illustrates the dose-response curve to endothelia alone. Table 2 represents the changes in perfusion pressure when low, sub-pressor doses of endothelia + MXA are given in comparision to MXA alone.
These findings demonstrate that the MXA concentration-response (perfusion pressure) relationship was shifted to lower concentrations by more than 10-fold, i.e., when low doses of endothelia and MXA which alone are sub-pressor were combined, the effect was a pronounced increase in vascular resistance. 'these findings demonstrate that low level endothelia stimulation in the penile vasculature will result in synergism when a-adrenergic receptors are activated.
Methods Animals Male Wistar rats (400-500 g), obtained from Charles River Laboratories (Montreal, Quebec, Canada), were housed individually under conditions of a 12 h light/12 h dark cycle (temperature of 22-24°C), and were provided with Purina Rodent Chow and tap water ad libitum for at least two days before starting any experiment.
Pudendal Perfusion Preparation The rats were anaesthetized with sodium pentabarbital (60 mg/1cg i.p.) and the lower abdominal aorta was exposed through a mid-line incision. 'The isolation of the pudendal vasculature was developed by sequential ligation of all branches of the abdominal aorta not directly supplying the pudendal vasculature. The following arteries were dissected free and ligated: iliaca, femoralis, poplitea, glutea cranial, umbilicalis, epigastria caudal, pudenda external, glutea caudal, obturatoria, circumflexa femoris lateral, circumflexa femoris medial. After heparinization (1000 U/kg), the abdominal aorta was cannulated with a smooth, blunted 19-gauge needle. The arterial catheter was placed caudad into the aorta and the vena cava was cut and vented freely through the widely open abdominal cavity. rl'he tip of the needle was advanced down the aorta to the iliac bifurcation and sutured in place. Flow of perfusate (0.5 mL/kg body weight/min) through the abdominal aorta was started immediately after transection, with sharp surgical scissors, of the abdominal aorta, inferior vena cava, spinal cord and all tissue 1 cm lateral to the spinal cord between T3 and T~ (Figure 2). The perfusate was infused for 10 min, to flush the penile vasculature of blood, before starting any experiment.
The perfusate consisted of dextran (15%, average molecular weight: 71,400 Da, Sigma, St. Louis, MO, U.S.A.) in Tyrode's solution (pH 7.4), which was aerated with 95%
Oz and 5% CO2. The composition of the Tyrode's solution was I~C1 20, CaCy2H20 32.3, MgClz~6H20 5.1, NaHzP04~2H20 6.2, NaI-IC03 100, glucose 100, and NaCI
mg per 100 mL fluid. The perfusate was held in a reservoir, and passed through a bubble trappin~mixing chamber and heating bath by an injection port located prior to the bubble trap for the introduction of pharmacological agents. An in-line peristaltic pump was used to establish flow at 0.5 mI/k~min (Minipuls 2, Gilson Medical Elec., Ine., Middleton, WI, U.S.A.). Added pharmacological agents, methoxamine (MXA) and sodium nitroprusside (SNP), were delivered by a syringe pump (Harvard Apparatus Infusion/Withdrawal Pump, Minis, MA, U.S.A.). A servo-controlled heat chamber served to maintain rectal temperature at 36-38°C.
Table 2: A comparision of the perfusion pressure responses in control and endothelia sub-pressor treated rats to the a,-adrenoceptor agonist methoxamine.
(D Perfusion Pressure (mmHg)) [methoxamine ~eg/ml Control Endothelia sub-pressor 0.1 0 0 0.25 0 34 _+2 0.5 0 93 _+ 30 1.0 4 + 1 168_+ 16 2.0 1 1 + 2 4.0 36 + 1 1 -8.0 67 + 24 -Values are expressed as group mean + S.D., n=6 for control, n=4 for endothelia sub-pressor.
Experiment: Effects of Endothelia Antagonists on Elockade of Apomorphine-induced Erections Lt is well known that NOS blockers (e.g., L-NAME) inhibit erectile response acutely. According to our novel understanding of normal vascular biology as described herein, we proposed that the mechanism of L-NAME-induced erectile dysfunction, at least acutely, is dependent on the activation of endothelia (ET)-mediated vasoconstriction, and can thus be reversed with an ET antagonist. This was confirmed experimentally as described below.
Methods Using the well-established apomorphine (APO)-induced erection model (apomorphine 80 ~,g/kg, administered subcutaneously), we counted the erections per 30 min interval in adult Wistar rats, per the protocol of Heaton, J.P.W., et al.
(1991)(43).
Rats were pretested with apomorphine alone to confirm and quantify normal erectile response(control Groups A and B). Rats were then treated with L-NAME ( 100 m~kg, administered intraperitoneally) alone, acutely (at < 1 h) and at 3 h; or the combination of ET,~ antagonist (PD 145065, 5 m~lcg/min, continuous intravenous infusion) + L-NAME.
Results Data represent mean number of erections ~ S.D. in the various different treatment groups. L-NAME alone blocked erection. Addition of the ET antagonist completely reversed acute L-NAME-induced decrease in erections, resulting in normal incidence of apomorphine-induced erections.
Group-A Group -B L-NAME-acute PD 145065 + L-NAME-3 h (control) (control) L-NAME
3.0 ~ 1.31 2.5 ~0.58 1.4 ~ 0.74** 2.5 ~ 0.58 3.7 ~ 1.38 ** indicates significant difference from control (p<0.01).
Conclusions The mechanism of decreased erectile function following acute L-NAME involves increased endothelin-mediated vasoconstriction.
By this experiment in combination with the foregoing, the inventors provide proof of concept of their novel model of normal vascular biology and of the use of endothelin antagonists in down regulating local endothelin-mediated vasoconstrictor tone and vascular growth activity in a patient independently of any normal or abnormal systemic physiology.
All scientific publications cited herein are hereby incorporated by reference.
Although this invention is described in detail with reference to preferred embodiments thereof, these embodiments, like the experiments described herein, are offered to illustrate but not to limit the invention. It is possible to make other embodiments that employ the principles of the invention and that fall within its spirit and scope as defined by the claims appended hereto.
" r . , References 1. Garg, U.C., and Hassid, A., J. ~3iol. (:hem. 266: 9-12 ( 1991 ).
2. Garg, U.C., and Hassid, A., J. Clin. Invest. 83: 1774-1777 (1989).
3. Palmer, R.M.J., et al., Nature 327: 524-526 (1987).
4. Assender, J.W., et al., J. Cardiovasc. 1'harmacol. 17(Suppl.3):
S 104-S 107 ( 1991 ).
5. O'Conner, ICJ., et al., J.Cardiovasc. Pharmacol. 17(Suppl.3):
S 100-S 103 ( 1991 ).
S 100-S 103 ( 1991 ).
6. Farhy, R.D., et al., Circ. Res. 72: 1202-1210 (1993).
7. Arnal, J.F., et al., J. Clin. Invest. 90: 647-652 (1992).
8. Manning, R.D., Jr., et al., J. Hypertension 21: 949-955 ( 1993).
9. Manning, R.D., Jr., et al., J. Hypertension 22: 40-48 ( 1993).
10. O'Conner, ICJ., et al., J. Cardiovasc. Pharmacol. 17(Suppl.3):
5100-S103 (1991 ).
5100-S103 (1991 ).
11. Morton, J.J., et al., J. Hypertension, 1 l: 1083-1088 ( 1993).
12. Richard, V., et al., Circ. 91: 771-775 (1995).
13. Schiffrin, E.L., et al., J. Hypertension 25(2): 769-773 (1995).
14. Schiffrin, E.L., and Thibault, G., Am. J. Hypertension 4( 1 ): 303-308 ( 1991 ).
15. Weber, H., et al., Mol. Endo. 8(2): 148-157 (1994).
16. Eddahibi, S., et al.,Ant. j. Plysiol. 268(2): H828-835 (1995).
17. IGnsey, A.C., et al., "Sexual Behavior in the Human Male", W.B. Saunders:
Philadelphia ( 1948).
I 8. Feldman, Henry A., et al., J. Urol. 151: 54-61 ( 1994).
19. Shabsigh, R., et al., Urology 32: 83-90 ( 1988).
20. Whitehead, E., Geriatrics 43(2): 114 ( 1988).
21. Furlow, W.L., et al., Med. Aspects Human Sexuality 19: 13-16 (1985).
22. Rajfer, J., et al., Netv Engl. J. Med. 326(2): 90-94 ( 1992).
23. Saenz de Tejada, L, et al., Am. J. Physiol 254: H459 (1988).
24. de Groat, W.C., and Steers, W.D., "Neuroanatomy and neurophysiology of penile erection" In: Contemporary Management of Impotence and Infertility (Tanagho, E.A., Lue, T.F., McClure, r.D., Eds.), Williams and Willcins (1988).
25. Lue, T.F., et al., J. Urol. 137(5): 829 (1987).
26. Juenemann, ICP., et al, J. Urol. 136(1): 158 (1986).
27. Lue, T.F., et al., J. Urol. 130: 1237 (1983).
28. Weiss, H., et al. , Ann. Intern. Med. 76: 793-799 ( 1980).
1~
29. Juencman, ICP., et al., Br. J. Llrol. 64-84 ( 1989).
30. Melman, A., and Henry, D., J. Urol. L 21: 419 ( 1979).
31. Benson, G.S., et al., J. Clin. Invest. 65: 506-513 ( 1980).
32. Hedlund, H., and Andersson, I<.E., J. Urol., 134: 1245 (1985).
r, i 33. Christ, G.J., et al.,''J. Pharmacol. 101: 375 (1990).
34. Wagner, G., and Brindley, G.S., "The effect of atrophine and c-blockers on human penile erection." In: Vasculogenic Impotence (Zorgniotti, A.W., Rossi, G., Eds.) Charles C. Thomas: Springfield, Ill., 77-81 ( 1980).
35. Adaikan, P. G., et al., J. Auton. Pharm. 3: 107 (1983).
36. Ignaro, L.J., et al., Biochem. Biophys. Res. Commun. 170:
843 ( 1990).
37. Gu, J., et al., J. Urol. 130: 386 ( 1983).
38. Gu, J., et al., Lancet 2: 315 ( 1984).
39. Willis, E., et al., Life. Sci. 33: 383 ( 1983).
40. Steif, C.G., et al., J. Urol. 143(2): 392-397 ( 1990).
41. Hedlund, H., and Andersson, ICE., J. Urol. 134: 1245 ( 1985).
42. Li, J.-S., and Schiffrin, E.L., J. I-lypertension 13(6):
647-652 (1995).
43. Heaton, J.P.W., et al., J. Urol. 145: 1099-1102 (1991).
SEQUENCE LISTING
(1) GENERAL INFORMATION:
(i) APPLICANT:
(A) NAME: Queen's University at Kingston (B) STREET: c/o PARTEQ Innovations (C) CITY: Kingston (D) STATE: Ontario (E) COUNTRY: Canada (F) POSTAL CODE (ZIP): K7L 3N6 (G) TET~EPHONE: (613) 545-2342 (H) TELEFAX: (613) 545-6853 (A) NAME: Banting, James D.
(B) STREET: 1038 Harcroft Court (C) CITY: Oakville (D) STATE: Ontario (E) COUNTRY: Canada (F) POSTAL CODE (ZIP): L6H 3K5 (A) NAME: Heaton, Jeremy P.W.
(B) STREET: R.R. #1 (C) CITY: Kingston (D) STATE: Ontario (E) COUNTRY: Canada (F) POSTAL CODE (ZIP): K7L 4V1 (A) NAME: Adams, Michael A.
(B) STREET: 341 Renda Street (C) CITY: Kingston (D) STATE: Ontario .
(E) COUNTRY: Canada (F) POSTAL CODE (ZIP): K7M 5X9 (ii) TITLE OF INVENTION: Antagonism of Endothelin Actions (iii) NUMBER OF SEQUENCES: 9 (iv) COMPUTER READABLE FORM:
(A) MEDIUM TYPE: Floppy disk (B) COMPUTER: IBM FC compatible (C) OPERATING SYSTEM: PC-DOS/MS-DOS
(D) SOFTWARE: PatentIn Release #1.0, Version #1.30 (EPO) (v) CURRENT APPLICATION DATA:
APPLICATION NUMBER: WO PCT/CA97/00169 (vi) PRIOR APPLICATION DATA:
(A) APPLICATION NUMBER: US 08/615,659 (B) FILING DATE: 13-MAR-1996 (2) INFORMATION FOR SEQ ID NO: 1:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 5 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: circular (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: Protein (B) LOCATION:1 (B) OTHER INFORMATION:/product= "OTHER"
/note= "D-Isomer of Tryptophan (DTrp)"
(ix) FEATURE:
(A) NAME/KEY: Protein (B) LOCATION:2 (D) OTHER INFORMATION:/product= "OTHER"
/note= "D-Isomer of Aspartic Acid (DAsp)"
(ix) FEATURE:
(A) NAME/KEY: Protein (B) LOCATION:4 (D) OTHER INFORMATION:/product= "OTHER"
/note= "D-Isomer of Valine (DVal)"
(xi) SEQUENCE DESCRIPTION: SEQ ID N0: 1:
Xaa Xaa Pro Xaa Leu (2) INFORMATION FOR SEø ID NO: 2:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 5 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: circular (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAMEjKEY: Protein (B) LOCATION:1 (D) OTHER INFORMATION:/product= "OTHER"
/note= "D-Isomer of Glutamic Acid (DGlu)"
(ix) FEATURE:
(A) NAMEjKEY: Protein (B) LOCATION:3 (D) OTHER INFORMATION:jproduct= "OTHER"
/note= "Allo-D Isoleucine: alpha-carbon is D; beta-carbon is L"
(ix) FEATURE:
(A) NAME/KEY: Protein (B) LOCATIONS
(D) OTHER INFORMATION:/product= "OTHER"
/note= "D-Isomer of Tryptophan (DTrp)"
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2:
Xaa Ala Xaa Leu Xaa (2) INFORMATION FOR SEQ ID NO. 3:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 5 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: circular (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: Protein (B) LOCATION:1 (D) OTHER INFORMATION:/product= "OTHER"
/note= "D-Isomer of Isoleucine (DIle)"
(ix) FEATURE:
(A) NAME/KEY: Protein (B) LOCATION:3 (D) OTHER INFORMATION:/product= "OTHER"
/note= "D-Isomer of Tryptaphan (DTrp)"
(ix) FEATURE:
(A) NAME/KEY: Protein (B) LOCATION:4 (D) OTHER INFORMATION:/product= "OTHER"
/note= "D-Isomer of Aspartic Acid (DAsp)"
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3:
Xaa Leu Xaa Xaa Pro (2) INFORMATION FOR SEQ ID NO: 4:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 5 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: circular (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: Protein (B) LOCATION:1 (D) OTHER INFORMATION:/product= "OTHER"
/note= "D-Isomer of Valine (DVal)"
(ix) FEATURE:
(A) NAME/KEY: Protein (B) LOCATION:3 (D) OTHER INFORMATION:/product= "OTHER"
/note= "D-Isomer of Tryptophan (DTrp)"
(ix) FEATURE:
(A) NAME/KEY: Protein (B) LOCATION:4 (D) OTHER INFORMATION:/product= "OTHER"
/note= "D-Isomer of Serine (DSer)"
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4:
Xaa Leu Xaa Xaa Pro (2) INFORMATION FOR SEQ ID NO: 5:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 3 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: Protein (B) LOCATION:1 (D) OTHER INFORMATION:/product= "OTHER"
/note= "Amino terminal-modified with (N,N-hexamethylene) carbamoyl"
(ix) FEATURE:
(A) NAME/KEY: Protein (B) LOCATION:2 (D) OTHER INFORMATION:/product= "OTHER"
/note= "D-Isomer of Tryptophan with formyl group on N of indole ring (DTrp (CHO) "
(ix) FEATURE:
(A) NAME/KEY: Protein (B) LOCATION:3 (D) OTHER INFORMATION:/product= "OTHER"
/note= "D-Isomer of Tryptophan (DTrp)"
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5:
Leu Xaa Xaa (2) INFORMATION FOR SEQ ID NO: 6:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 5 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: circular (ii) MOLECULE TYPE: peptide 2~
(ix) FEATURE:
(A) NAME/KEY: Protein (B) LOCATION:1 (D) OTHER INFORMATION:/product= "OTHER"
/note= "D-Isomer of Glutamic Acid (DGlu)"
(ix) FEATURE:
(A) NAME/KEY: Protein (B) LOCATION:3 (D) OTHER INFORMATION:/product= "OTHER"
/note= "D-Isomer of Valine (DVal)"
(ix) FEATURE:
(A) NAME/KEY: Protein (B) LOCATION:5 (D) OTHER INFORMATION:/product= "OTHER"
/note= "D-Isomer of Tryptophan (DTrp)"
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 6:
Xaa Ala Xaa Leu Xaa (2) INFORMATION FOR SEQ ID NO: 7:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 5 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: circular (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: Protein (B) LOCATION;1 (D) OTHER INFORMATION:/product= "OTHER"
/note= "D-Isomer of Glutamic Acid (DGlu)"
(ix) FEATURE:
(A) NAME/KEY: Protein (B) LOCATION:3 (D) OTHER INFORMATION:/product= "OTHER"
/note= "D-Isomer of Valine (DVal)"
(ix) FEATURE;
(A) NAME/KEY: Protein (B) LOCATION:5 (D) OTHER INFORMATION:/product= "OTHER"
/note= "D-Isomer of Trptophan (DTrp)"
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 7:
Xaa Ala Xaa Leu Xaa i ~ _.
(2) INFORMATION FOR SEQ ID NO: 8:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: Protein (B) LOCATION:1 (D) OTHER INFORMATION:/product= "OTHER"
/note= "Amino group of Leucine is acetylated (Ac-Leu)"
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 8:
Leu Met Asp Lys Glu Ala Tyr Phe Ala His Leu Asp Ile Ile Trp (2) INFORMATION FOR SEQ ID N0: 9:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: Protein (B) LOCATION:1 (D) OTHER INFORMATION:/product= "OTHER"
/note= "Sucrose is attached to N-terminal of Aspartic Acid (Suc-Asp)"
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 9:
Asp Glu Glu Ala Val Tyr Phe Ala His Leu Asp Ile Ile Trp 2 (~
Philadelphia ( 1948).
I 8. Feldman, Henry A., et al., J. Urol. 151: 54-61 ( 1994).
19. Shabsigh, R., et al., Urology 32: 83-90 ( 1988).
20. Whitehead, E., Geriatrics 43(2): 114 ( 1988).
21. Furlow, W.L., et al., Med. Aspects Human Sexuality 19: 13-16 (1985).
22. Rajfer, J., et al., Netv Engl. J. Med. 326(2): 90-94 ( 1992).
23. Saenz de Tejada, L, et al., Am. J. Physiol 254: H459 (1988).
24. de Groat, W.C., and Steers, W.D., "Neuroanatomy and neurophysiology of penile erection" In: Contemporary Management of Impotence and Infertility (Tanagho, E.A., Lue, T.F., McClure, r.D., Eds.), Williams and Willcins (1988).
25. Lue, T.F., et al., J. Urol. 137(5): 829 (1987).
26. Juenemann, ICP., et al, J. Urol. 136(1): 158 (1986).
27. Lue, T.F., et al., J. Urol. 130: 1237 (1983).
28. Weiss, H., et al. , Ann. Intern. Med. 76: 793-799 ( 1980).
1~
29. Juencman, ICP., et al., Br. J. Llrol. 64-84 ( 1989).
30. Melman, A., and Henry, D., J. Urol. L 21: 419 ( 1979).
31. Benson, G.S., et al., J. Clin. Invest. 65: 506-513 ( 1980).
32. Hedlund, H., and Andersson, I<.E., J. Urol., 134: 1245 (1985).
r, i 33. Christ, G.J., et al.,''J. Pharmacol. 101: 375 (1990).
34. Wagner, G., and Brindley, G.S., "The effect of atrophine and c-blockers on human penile erection." In: Vasculogenic Impotence (Zorgniotti, A.W., Rossi, G., Eds.) Charles C. Thomas: Springfield, Ill., 77-81 ( 1980).
35. Adaikan, P. G., et al., J. Auton. Pharm. 3: 107 (1983).
36. Ignaro, L.J., et al., Biochem. Biophys. Res. Commun. 170:
843 ( 1990).
37. Gu, J., et al., J. Urol. 130: 386 ( 1983).
38. Gu, J., et al., Lancet 2: 315 ( 1984).
39. Willis, E., et al., Life. Sci. 33: 383 ( 1983).
40. Steif, C.G., et al., J. Urol. 143(2): 392-397 ( 1990).
41. Hedlund, H., and Andersson, ICE., J. Urol. 134: 1245 ( 1985).
42. Li, J.-S., and Schiffrin, E.L., J. I-lypertension 13(6):
647-652 (1995).
43. Heaton, J.P.W., et al., J. Urol. 145: 1099-1102 (1991).
SEQUENCE LISTING
(1) GENERAL INFORMATION:
(i) APPLICANT:
(A) NAME: Queen's University at Kingston (B) STREET: c/o PARTEQ Innovations (C) CITY: Kingston (D) STATE: Ontario (E) COUNTRY: Canada (F) POSTAL CODE (ZIP): K7L 3N6 (G) TET~EPHONE: (613) 545-2342 (H) TELEFAX: (613) 545-6853 (A) NAME: Banting, James D.
(B) STREET: 1038 Harcroft Court (C) CITY: Oakville (D) STATE: Ontario (E) COUNTRY: Canada (F) POSTAL CODE (ZIP): L6H 3K5 (A) NAME: Heaton, Jeremy P.W.
(B) STREET: R.R. #1 (C) CITY: Kingston (D) STATE: Ontario (E) COUNTRY: Canada (F) POSTAL CODE (ZIP): K7L 4V1 (A) NAME: Adams, Michael A.
(B) STREET: 341 Renda Street (C) CITY: Kingston (D) STATE: Ontario .
(E) COUNTRY: Canada (F) POSTAL CODE (ZIP): K7M 5X9 (ii) TITLE OF INVENTION: Antagonism of Endothelin Actions (iii) NUMBER OF SEQUENCES: 9 (iv) COMPUTER READABLE FORM:
(A) MEDIUM TYPE: Floppy disk (B) COMPUTER: IBM FC compatible (C) OPERATING SYSTEM: PC-DOS/MS-DOS
(D) SOFTWARE: PatentIn Release #1.0, Version #1.30 (EPO) (v) CURRENT APPLICATION DATA:
APPLICATION NUMBER: WO PCT/CA97/00169 (vi) PRIOR APPLICATION DATA:
(A) APPLICATION NUMBER: US 08/615,659 (B) FILING DATE: 13-MAR-1996 (2) INFORMATION FOR SEQ ID NO: 1:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 5 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: circular (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: Protein (B) LOCATION:1 (B) OTHER INFORMATION:/product= "OTHER"
/note= "D-Isomer of Tryptophan (DTrp)"
(ix) FEATURE:
(A) NAME/KEY: Protein (B) LOCATION:2 (D) OTHER INFORMATION:/product= "OTHER"
/note= "D-Isomer of Aspartic Acid (DAsp)"
(ix) FEATURE:
(A) NAME/KEY: Protein (B) LOCATION:4 (D) OTHER INFORMATION:/product= "OTHER"
/note= "D-Isomer of Valine (DVal)"
(xi) SEQUENCE DESCRIPTION: SEQ ID N0: 1:
Xaa Xaa Pro Xaa Leu (2) INFORMATION FOR SEø ID NO: 2:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 5 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: circular (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAMEjKEY: Protein (B) LOCATION:1 (D) OTHER INFORMATION:/product= "OTHER"
/note= "D-Isomer of Glutamic Acid (DGlu)"
(ix) FEATURE:
(A) NAMEjKEY: Protein (B) LOCATION:3 (D) OTHER INFORMATION:jproduct= "OTHER"
/note= "Allo-D Isoleucine: alpha-carbon is D; beta-carbon is L"
(ix) FEATURE:
(A) NAME/KEY: Protein (B) LOCATIONS
(D) OTHER INFORMATION:/product= "OTHER"
/note= "D-Isomer of Tryptophan (DTrp)"
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2:
Xaa Ala Xaa Leu Xaa (2) INFORMATION FOR SEQ ID NO. 3:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 5 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: circular (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: Protein (B) LOCATION:1 (D) OTHER INFORMATION:/product= "OTHER"
/note= "D-Isomer of Isoleucine (DIle)"
(ix) FEATURE:
(A) NAME/KEY: Protein (B) LOCATION:3 (D) OTHER INFORMATION:/product= "OTHER"
/note= "D-Isomer of Tryptaphan (DTrp)"
(ix) FEATURE:
(A) NAME/KEY: Protein (B) LOCATION:4 (D) OTHER INFORMATION:/product= "OTHER"
/note= "D-Isomer of Aspartic Acid (DAsp)"
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3:
Xaa Leu Xaa Xaa Pro (2) INFORMATION FOR SEQ ID NO: 4:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 5 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: circular (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: Protein (B) LOCATION:1 (D) OTHER INFORMATION:/product= "OTHER"
/note= "D-Isomer of Valine (DVal)"
(ix) FEATURE:
(A) NAME/KEY: Protein (B) LOCATION:3 (D) OTHER INFORMATION:/product= "OTHER"
/note= "D-Isomer of Tryptophan (DTrp)"
(ix) FEATURE:
(A) NAME/KEY: Protein (B) LOCATION:4 (D) OTHER INFORMATION:/product= "OTHER"
/note= "D-Isomer of Serine (DSer)"
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4:
Xaa Leu Xaa Xaa Pro (2) INFORMATION FOR SEQ ID NO: 5:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 3 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: Protein (B) LOCATION:1 (D) OTHER INFORMATION:/product= "OTHER"
/note= "Amino terminal-modified with (N,N-hexamethylene) carbamoyl"
(ix) FEATURE:
(A) NAME/KEY: Protein (B) LOCATION:2 (D) OTHER INFORMATION:/product= "OTHER"
/note= "D-Isomer of Tryptophan with formyl group on N of indole ring (DTrp (CHO) "
(ix) FEATURE:
(A) NAME/KEY: Protein (B) LOCATION:3 (D) OTHER INFORMATION:/product= "OTHER"
/note= "D-Isomer of Tryptophan (DTrp)"
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5:
Leu Xaa Xaa (2) INFORMATION FOR SEQ ID NO: 6:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 5 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: circular (ii) MOLECULE TYPE: peptide 2~
(ix) FEATURE:
(A) NAME/KEY: Protein (B) LOCATION:1 (D) OTHER INFORMATION:/product= "OTHER"
/note= "D-Isomer of Glutamic Acid (DGlu)"
(ix) FEATURE:
(A) NAME/KEY: Protein (B) LOCATION:3 (D) OTHER INFORMATION:/product= "OTHER"
/note= "D-Isomer of Valine (DVal)"
(ix) FEATURE:
(A) NAME/KEY: Protein (B) LOCATION:5 (D) OTHER INFORMATION:/product= "OTHER"
/note= "D-Isomer of Tryptophan (DTrp)"
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 6:
Xaa Ala Xaa Leu Xaa (2) INFORMATION FOR SEQ ID NO: 7:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 5 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: circular (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: Protein (B) LOCATION;1 (D) OTHER INFORMATION:/product= "OTHER"
/note= "D-Isomer of Glutamic Acid (DGlu)"
(ix) FEATURE:
(A) NAME/KEY: Protein (B) LOCATION:3 (D) OTHER INFORMATION:/product= "OTHER"
/note= "D-Isomer of Valine (DVal)"
(ix) FEATURE;
(A) NAME/KEY: Protein (B) LOCATION:5 (D) OTHER INFORMATION:/product= "OTHER"
/note= "D-Isomer of Trptophan (DTrp)"
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 7:
Xaa Ala Xaa Leu Xaa i ~ _.
(2) INFORMATION FOR SEQ ID NO: 8:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: Protein (B) LOCATION:1 (D) OTHER INFORMATION:/product= "OTHER"
/note= "Amino group of Leucine is acetylated (Ac-Leu)"
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 8:
Leu Met Asp Lys Glu Ala Tyr Phe Ala His Leu Asp Ile Ile Trp (2) INFORMATION FOR SEQ ID N0: 9:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: Protein (B) LOCATION:1 (D) OTHER INFORMATION:/product= "OTHER"
/note= "Sucrose is attached to N-terminal of Aspartic Acid (Suc-Asp)"
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 9:
Asp Glu Glu Ala Val Tyr Phe Ala His Leu Asp Ile Ile Trp 2 (~
Claims (26)
1. A method for treating physiological conditions in which NO production is inhibited such that at least one of vasoconstrictor tone and vascular growth is increased, comprising the step of administering to a patient in need thereof an effective amount of an agent which antagonizes action of endothelin, in a pharmaceutically acceptable carrier therefor.
2. A method as claimed in claim 1 wherein said agent is selected from the group consisting of peptidal endothelin antagonists, non-peptidal endothelin antagonists, inhibitors of endothelin converting enzyme, and antisense oligonucleotides which block translation of mRNA encoding endothelin or an endothelin precursor protein.
3. A method as claimed in claim 2 wherein said peptidal endothelin antagonist is an ET A/ET B receptor antagonist.
4. A method as claimed in claim 2 wherein said non-peptidal endothelin antagonist is bosentan.
5. A method as claimed in claim 2 wherein said inhibitor of endothelin converting enzyme is phosphoramidon.
6. A method as claimed in claim 1 wherein said physiological condition, in which NO
production is inhibited such that at least one of vasoconstrictor tone and vascular growth is increased, is erectile dysfunction.
production is inhibited such that at least one of vasoconstrictor tone and vascular growth is increased, is erectile dysfunction.
7. A method as claimed in claim 2 wherein said agent is administered orally.
8. A method as claimed in claim 2 wherein said agent is administered intraperitoneally.
9. A method as claimed in claim 3 wherein said ET A/ET B receptor antagonist is PD145065.
10. A method as claimed in claim 9 wherein said PD145065 is administered intraperitoneally.
11. Use of an endothelin antagonist in the preparation of a medicament for treatment of physiological conditions in which NO production is inhibited such that at least one of vasoconstrictor tone or vascular growth is increased, wherein an effective amount of said endothelin antagonist is mixed with a pharmaceutically acceptable carrier therefor.
12. Use as claimed in claim 11 wherein said endothelin antagonist is selected from the group consisting of peptidal endothelin antagonists, non-peptidal endothelin antagonists, inhibitors of endothelin converting enzyme and antisense oligonucleotides which block translation of mRNA encoding endothelin or an endothelin precursor protein.
13. Use as claimed in claim 12 wherein said peptidal endothelin antagonist is an ET A/ET B receptor antagonist.
14. Use as claimed in claim 13 wherein said ET A/ET B receptor antagonist is PD145065.
15. Use as claimed in claim 12 wherein said non-peptidal endothelin antagonist is bosentan.
16. Use as claimed in claim 12 wherein said inhibitor of endothelin converting enzyme is phosphoramidon.
17. Use as claimed in claim 12 wherein said agent is an ET A receptor antagonist.
18. Use as claimed in claim 12 wherein said agent is an ET B receptor antagonist.
19. A method for down regulating local endothelin-mediated vasoconstrictor tone and vascular growth activity in a patient independently of any normal or abnormal systemic physiology, comprising the step of administering to the patient an effective amount of an agent which antagonizes action of endothelin, in a pharmaceutically acceptable carrier therefor.
20. A method as claimed in claim 19 wherein said agent is selected from the group consisting of peptidal endothelin antagonists, non-peptidal endothelin antagonists, inhibitors of endothelin converting enzyme, and antisense oligonucleotides which block translation of mRNA encoding endothelin or an endothelin precuror protein.
21. A method as claimed in claim 20 wherein said peptidal endothelin antagonist is an ET A/ET B receptor antagonist.
22. A method as claimed in claim 19 wherein said vasoconstrictor tone is selected from the group consisting of the tone of the pudendal vasculature, the tone of the arteries feeding the pudendal vasculature, and a combination thereof.
23. Use of an endothelin antagonist in the preparation of a medicament for down regulation of local endothelin-mediated vasoconstrictor tone and vascular growth activity in a patient independently of any normal or abnormal systemic physiology, wherein an effective amount of said endothelin antagonist is mixed with a pharmaceutically acceptable carrier therefor.
24. Use as claimed in claim 23 wherein said agent is selected from the group consisting of peptidal endothelin antagonists, non-peptidal endothelin antagonists, inhibitors of endothelin converting enzyme and antisense oligonucleotides which block translation of mRNA encoding endothelin or an endothelin precursor protein.
25. Use as claimed in claim 24 wherein said peptidal endothelin antagonist is an ET A/ET B receptor antagonist.
26. Use as claimed in claim 23 wherein said vasoconstrictor tone is selected from the group consisting of the tone of the pudendal vasculature, the tone of the arteries feeding the pudendal vasculature, and a combination thereof.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/615,659 US5688499A (en) | 1996-03-13 | 1996-03-13 | Antagonism of endothelin actions |
US08/615,659 | 1996-03-13 | ||
CA2,248,047 | 1997-03-13 | ||
CA002248047A CA2248047C (en) | 1996-03-13 | 1997-03-13 | Antagonism of endothelin actions |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002248047A Division CA2248047C (en) | 1996-03-13 | 1997-03-13 | Antagonism of endothelin actions |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2391818A1 true CA2391818A1 (en) | 1997-09-18 |
Family
ID=25680504
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002391818A Abandoned CA2391818A1 (en) | 1996-03-13 | 1997-03-13 | Antagonism of endothelin actions |
Country Status (1)
Country | Link |
---|---|
CA (1) | CA2391818A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007137980A1 (en) | 2006-05-29 | 2007-12-06 | Nicox S.A. | Nitrated heterocyclic compounds as endothelin receptor antagonist |
-
1997
- 1997-03-13 CA CA002391818A patent/CA2391818A1/en not_active Abandoned
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007137980A1 (en) | 2006-05-29 | 2007-12-06 | Nicox S.A. | Nitrated heterocyclic compounds as endothelin receptor antagonist |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0888123B1 (en) | Antagonism of endothelin actions | |
EP0998274B1 (en) | Microdose therapy of vascular conditions by no donors | |
US20040063719A1 (en) | Combination therapy using antihypertensive agents and endothelin antagonists | |
CA2340206A1 (en) | Use of anti-pressor agents for vascular remodeling in genital dysfunction | |
Cirino et al. | Pharmacology of erectile dysfunction in man | |
AU748846B2 (en) | Amelioration of erectile dysfunction with apomorphine and an agent that antagonizes endothelin actions | |
CA2391818A1 (en) | Antagonism of endothelin actions | |
Saito et al. | Renin inhibitor and converting enzyme inhibitors suppress vascular angiotensin II. | |
MXPA98007420A (en) | Antagonism of endotel actions | |
Melman et al. | Male Sexual Dysfunction in Diabetes Mellitus | |
KR19990087758A (en) | Antagonism of Endorinline Activity | |
EP1842538A2 (en) | Treatment for Raynaud's Phenomenon | |
AU2002311264B2 (en) | Microdose therapy | |
EP1535611A2 (en) | Microdose therapy of vascular conditions by no donors | |
AU2008201350A1 (en) | Microdose therapy | |
US20040138291A1 (en) | Treatment of sexual dysfunction | |
AU2005244522A1 (en) | Microdose therapy | |
Cosenzi | The antagonists of endothelin receptors: results and perspectives | |
Arulmani | Calcitonin Gene-Related Peptide and Migraine: Implications for Therapy | |
Ballew | Relationship between experimental angiotensin II induced hypertension and activation of the endothelin system in male rats: effects of salt intake | |
Hannan | Evidence Linking the Structure and Function of the Internal Pudendal Artery to Erectile Function: Impact of Aging, Hypertension, Antihypertensive Treatments and Lifestyle Modifications | |
Coleman et al. | The Effects of Converting Enzyme Inhibition | |
Ertemi | The Role of Angiotensin II on Human and Partial Bladder Outlet Obstructed Rabbit Corpus Cavernosal Contractility: Modulation of Nitric Oxide-mediated Relaxation and Relevance to Erectile Dysfunction | |
Mampouma et al. | Early induction of erectile dysfunction by angiotensin II in rat | |
上野倫彦 | Combination of oral endothelin-A receptor antagonist and oral prostacyclin analogue is superior to each drug alone in ameliorating pulmonary hypertension in rats |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
FZDE | Dead |